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Abstract: The review presents a broad overview of the biomedical applications of surface 
functionalized iron oxide nanoparticles (IONPs) as magnetic resonance imaging (MRI) agents for 
sensitive and precise diagnosis tool and synergistic combination with other imaging modalities. 
Then, the recent progress in therapeutic applications, such as hyperthermia is discussed and the 
available toxicity data of magnetic nanoparticles concerning in vitro and in vivo biomedical 
applications are addressed. This review also presents the available computer models using 
molecular dynamics (MD), Monte Carlo (MC) and density functional theory (DFT), as a basis for a 
complete understanding of the behaviour and morphology of functionalized IONPs, for improving 
NPs surface design and expanding the potential applications in nanomedicine.  
Keywords: magnetic iron oxide nanoparticles; computational modelling; biomedical application; 
imaging; toxicity 
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1. Introduction 
Iron oxide based magnetic nanoparticles (IONPs) have received remarkable attention in a 
wide range of applications because of their unique physicochemical properties inherent to the 
nanoscale. Small size, high surface area, quantum confinement, and novel magnetic and optical 
effects open up new fields for application of iron oxides. For instance, conventional magnetic 
materials (ferromagnetic iron oxides) lose their permanent magnetization if they are studied or used 
as nanoparticles [1, 2]. Parallel to the practical uses of magnetic IONPs in electronics and catalysis, 
they are widely considered since decades for magnetic hyperthermia goals (local heat source in the 
case of tumour therapy) [3] and as contrast agents for magnetic resonance imaging (MRI) [4, 5, 6]. 
Since then, the switchable magnetic properties of IONPs makes them attractive for a rapidly 
expanding number of bioapplications: labelling and sorting of cells, cell transfection, enhance 
diagnostic imaging output like in magnetic resonance imaging (MRI), positron emission 
tomography (PET), tissue-specific drug/gene delivery systems, for magnetic hyperthermia treatment 
or as multifunctional nanoplatforms for magnetic theranostic by a combination of two or more of 
the corresponding applications [7-10, 2]. 
The IONPs show ability for the biomedical application; they need to possess suitable core 
size and monodispersity, acceptable hydrodynamic diameter, high saturation magnetisation (Ms), 
high stability in biological fluid media, to be bio-compatible and degradable with reduced toxicity 
over a large time scale, capable of clearance from the body post imaging. The used nanosystems 
consist of iron oxide single-core or multi-cores and shell/s ensuring the colloidal stability in the 
biological environment, limiting the non-specific adsorption of biomolecules and fulfilling the roles 
of anchors, spacers and various functionalities. The single-core nanoparticles contain single-domain 
nanocrystal per particle, while the multi-core nanoparticles consist of superparamagnetic particles 
(~10 nm) which form moderate ferrimagnetic clusters (from 20 to 80 nm) [11].  
The magnetic behaviour of IONPs is crucial for their effectiveness in biomedical 
applications, partially based on their superparamagnetic properties. Therefore, IONPs often are 
labelled as SPIONs (superparamagnetic iron oxide nanoparticles). Superparamagnetism is a 
property occurring principally in nanoparticles which are single-domain and can be attributed to 
their size [1, 2]. The dependence of magnetic properties of SPIONs on the specific composition, 
structure, size, size distribution, shape and thickness of surface coating are the object of extensive 
studies, part of which are summarised in [12-16]. The rheological behaviour of the ferrofluids 
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containing IONPs also is a subject of investigation, e.g. [17, 18], since the knowledge about 
changes under an external magnetic field to ensure safe and efficient treatment of living organisms 
is essential.  
The procedures for synthesis/surface coating/encapsulation, their effect on the 
physicochemical properties, and potential field of biomedical applications of SPIONs are reviewed 
throughout the years [16, 19-29]. A very detailed analysis of the advantages and disadvantages of 
different synthesis methods is given in [27], while in reviews [16, 29] the focus is on the 
classification of the proven synthesis routes based on their capacity to produce either single-core or 
multi-core nanoparticles. The special attention is paid to the fact that the choice must obey to their 
specific biomedical application [29] as it is also presented in Ref. [11] because not only the 
magnetic properties of single- and multi-core NPs are different [11, 30], but also the rheological 
behaviour of the corresponding ferrofluids [17]. 
The main synthesis routes for the preparation of SPIONs are well established during the last 
two decades, and some of them like co-precipitation, mild oxidative hydrolysis and thermal 
decomposition are readily available for producing IONPs in semi-industrial quantities. Initially, 
variations in the procedures were dealing not with the core but mainly with the stages of 
stabilisation, as well as in the surface modification so that the final product to be biocompatible and 
suitable for further coupling with different features like fluorescent dyes, drugs or specific bioactive 
molecules. In the last decade, the studies are directly related to the final specific application of 
SPIONs and cover mainly: i) tuning of the magnetic properties by changing the shape, by 
controlling size and size distribution, by using multi-core IONPs or assembling; ii) obtaining 
multimodal hybrid structures for theranostic applications by surface functionalization with universal 
ligands iii) producing safety nanoplatforms with sufficient colloidal stability in biological media 
and long circulation time [31-39]. 
Despite the vast amount of papers and the evidences for the potential applicability of 
SPIONs in nanomedicine, it has to be taken into account that a limited  part of the reported 
synthesis procedures is in resonance with the nano-safety regulatory framework, and respectively, a 
minor part of these innovative nanoplatforms could find real biomedical implementation [40-42]. 
Moreover, even some of the designed for clinical application and tested MR contrast agents did not 
receive regulatory approval (Clariscan®/VSOP C184). Others (Endorem®, Lumirem®/ 
GastroMARK®) received approval, however, they were taken off the market while some of the 
approved (Resovist®, Ferumoxytol) were currently available in quite few countries [43, 44].  
The presented Review is widely focused on the biomedical application of iron oxide 
nanoparticles, considered from in vitro, in vivo and in silico aspects. The Review is organized as 
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follows: in the first part a brief overview of the development of magnetic iron oxide nanoparticles 
as MR imaging agents and their synergistic integration with other imaging modalities is given, the 
second part covers recent progress in the usage of SPIONs for in vitro and in vivo cancer theranostic 
applications; then the focus is on currently available in vitro and in vivo toxicity data. In the final 
part of the review, we provide an overview of the current state of the field in theoretical studies of 
iron oxide nanoparticles. The novelty of our vision comes from assembling broad combinations of 
different approaches to the subject pointed to the potential of the iron oxide nanoparticles to become 
a useful platform material for theranostics and personalised medicine.  
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2. Biomedical applications of SPIONs 
2.1. Magnetic Resonance Imaging 
The progressive development of new imaging modality became conceivable due to the recent 
progress in nanotechnology, molecular and cell biology, and imaging technologies. Diversity in types 
of imaging techniques has inherent advantages and disadvantages. While molecular imaging applies to 
various techniques such as positron emission tomography (PET), computed tomography (CT), or 
ultrasound, of particular interest is the magnetic resonance imaging (MRI) that provides the best spatial 
resolution and it is noninvasive or at least minimally invasive [19, 21].  
MRI is with excellent (submillimeter) spatial resolution, and it also avoids the radiation 
exposure, like in PET and CT. Additionally, soft tissue contrast is outstanding, and MRI readily yields 
anatomical information [45]. Conventional MRI has not been applied to its full potential for the 
diagnosis of cancer in the general case, because of incorrect results concerning its quite low sensitivity 
(false-positive rate of 10% for breast cancer). By nuclear magnetic resonance and optical imaging 
technologies, the ability to fight with cancer could vastly enhance, and these methods still represent the 
mainstay of clinical imaging.  
 
Fig. 1. Basic MRI principle: conventional MRI is based on the radiofrequency signal that is transmitted 
from the atomic nucleus of hydrogen atoms placed in a magnetic field and after they have been excited 
by a radiofrequency electromagnetic pulse ([Yves De Deene - Hyperpolarized MRI - 
http://slideplayer.com/slide/5049588/] and authors view). 
 
MRI for a biomedical imaging technique used to image soft tissues of the human body in very 
thin slices in two-dimensional as well as three-dimensional spaces (Fig. 1). The water present in our 
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body plays a major role in obtaining MRI images [46]. The hydrogen nucleus in water tends to align 
them in a direction parallel to the applied external magnetic field. Then a radiofrequency (RF) signal is 
applied to change the direction of alignment of protons in the hydrogen nucleus, where the frequency 
of the RF signal must be in resonance with the frequency of the hydrogen nucleus. As the directions of 
the protons are changed after applying the RF signal, the protons tend to re-align with the applied 
magnetic field. So while returning to its original position, these protons release energy as an RF signal 
that can be detected by detectors in MRI machine. The re-alignment speed of protons varies for various 
tissues in our body, which is helpful in imaging such tissues precisely and the time taken for this re-
alignment is called the relaxation time. Relaxation processes are two types: longitudinal relaxation 
(also called spin−lattice relaxation) and transverse relaxation (also called spin−spin relaxation).  
The T1 relaxation time is characterised by the time required for longitudinal magnetisation to 
recuperate from zero to a value of 63% of the original state. The transverse magnetisation of the 
protons decays as the nuclear spins is dephased, which is the transverse relaxation. The time for the 
transverse magnetisation and drop from the maximum to a value of 37% of its excited state value is the 
T2 relaxation time. The relaxivities (r1 and r2), that change with the applied magnetic field in 
longitudinal and transverse directions, are the inverse of the relaxation times at the respective directions 
(i.e., r1 = 1/T1; r2 = 1/T2), where the ratio of relaxivities is significant in deciding the fate of the 
nanoparticles to be used either as a positive or a negative contrast. Both T1 and T2 relaxations are 
dependent on the saturation magnetisation of nanoparticles and their magnetic interactions with the 
protons of surrounding water molecules.  
The sensitivity of MRI can be significantly improved by the agents that enhance the contrast of 
the region of interest from the background. Numerous parameters like size of the iron oxide crystals, 
type of the coating, and hydrodynamic size of the coated NPs, polydispersity, and surface charge of 
SPIONs as MRI contrast agents accomplish their productivity and efficiency. The colloidal stability 
depends in general, on these characteristics and has a significant impact on the: cellular uptake, protein 
adsorption and interactions with biological membranes, and biokinetic parameters such as 
biodistribution, biodegradation, metabolism, and elimination (see Fig. 2). Numerous examples are 
summarised in the reviews of Laurent, Mahmoudi, et al. [47, 48].  
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Fig. 2. The different physiochemical properties of SPIONs affect their biokinetics and fate in vivo. 
These changes can be observed in uptake, distribution, metabolism, and excretion of SPIONs from the 
body. Protein corona is yet another factor that is influenced by various physiochemical features of NPs 
and can, in turn, affect the targeting capabilities of SPIONs in imaging applications. Not only can 
protein corona alter the toxicity, uptake, targeting, and circulation time of SPIONs, but it can also affect 
the relaxivity of SPIONs as MRI contrast agents. - Reproduced from [48] with permission from the 
Wiley. Copyright 2015. 
MRI contrast agents can be divided into two groups, i.e. positive contrast agents (or T1-
weighted contrast agents) and negative contrast agents (or T2-weighted contrast agents). The positive 
contrast agents shorten the longitudinal relaxation times (T1) of protons, resulting in a brighter image in 
T1-weighted MRI and produce an increase in the NMR signal intensity. The negative contrast agents 
shorten both the transverse relaxation times (T2) of protons and free induction decay time (T2
*
) leading 
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to the darker image in T2- and T2
*
-weighted MRI and produce a decrease. The contrast agent does not 
produce a signal itself, but it marks the proton relaxation rate. Thus, the contrast between healthy and 
diseased tissues can be attained by varying number of protons and T1 and T2 relaxation times, similar to 
NMR. The ratio between transverse and longitudinal relaxivity (r2/r1) is an important parameter to 
estimate the efficiency of T1 or T2 contrast agents. The high r2/r1 ratio (>8) results in T2-dominated 
contrast and the lower ratio (<5) leads to T1-dominated contrast [49].  
The T1-contrast agents, approved for clinical use are prevailingly paramagnetic complexes, such 
as Gd
3+
 based chelates. They have low relaxivity r2/r1 ratio (commonly in the range of 1-2). On the 
contrary, the negative contrast agents are predominantly supermagnetic IONPs with a high r2/r1 ratio (> 
5, commonly at least 10). This high relaxivity ratio limits in most cases the use of SPIONs in T1-
weighted MRI although a significant reducing of T1 is observed, often higher as compared to the 
paramagnetic chelates.  
However, each of clinical approved contrast agents has some disadvantages. The Gd-based 
chelates suffer for poor physiological stability, short life span, poor cellular uptake, nonspecificity to 
target and may cause induction of nephrogenic systemic fibrosis [50]. The overviews of the risks, 
related to the Gd-based contrast agents have been made in Refs. [51, 51]. On the other hand, although 
SPIONs are traditionally considered as much more efficient in MR relaxation than paramagnetic 
agents, their significant obstacles are magnetic susceptibility artefacts and negative contrast effects 
(i.e., dark MR images). Also, some of the approved for clinical use formulations had been withdrawn 
from the market due to the economic or safety concerns [43]. In just published literature update of 
clinical researchers of SPIONs for MRI [44] the opportunities and challenges for the clinical 
development of SPIO agents are pointed out. So, the development of novel, more efficient and safety 
formulations remains a challenge for the scientific community, in particular for the chemists and with 
the main impact of the chemical community like a driving force to move the field forward [53]. The 
IONPs are preferable object in research because of 1) their excellent biocompatibility; 2) the possibility 
of tunning their magnetic properties, respectively ratio r2/r1, by changing the composition, size or 
shape; 3) the possibility for surface modification, with different features like bioactive, therapeutic and 
signaling molecules, thus tailoring their application not only in imaging. Some examples of the 
achieved results and applicability of IONPs for MRI imaging are given, and some of the available 
recent published data are summarised in Table 1 in the supplement information. 
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2.1.1  T1 contrast agent  
For precise, high-resolution imaging, the T1 contrast agent is more desirable than T2. Although 
the SPIONs are conventionally considered as negative contrast agents, by reducing the size and 
preventing aggregation using proper coatings, a low magnetisation, respectively low r2 values and r2/r1 
ratios could be achieved, so the SPIONs can also surve as positive contrast agents. 
As explained already in the Introduction part the size greatly distresses the magnetic properties 
of the nanoparticles. The magnetic spins of the nanoparticle surface are disordered owing to the unique 
state of the surface atoms, which is called the spin-canting effect [54, 55]. The canted spins can be 
enhanced by reducing the size of nanoparticles because of the intensification of the spin-canting layer 
portion in the nanoparticles, and this is the basis for the T1 contrast effect.  
The inter-relationship between the size, magnetisation and spin-canted surface layer can be 
express by Eq. (1) 
  ms = Ms[(r-d/r)]
3
           (1), 
where ms is saturation magnetisation of the size-reduced nanoparticle, Ms is saturation magnetisation of 
the bulk materials, r is the size of nanoparticle and d is the thickness of the disordered surface layer. 
Kim et al. [56] estimated that about 93.6% of the surface spins in 3-nm sized iron oxide nanoparticles 
were canted as compared to 38.6% of surface spins in 12-nm sized nanoparticles. As a result of the 
increased canting effects in 3 nm sized iron oxide nanoparticles, the magnetisation values decreased 
correspondingly. As the size of the particle decreases to < 3 nm, the magnetic spins are canted, thus, the 
overall magnetic behaviour is nearly paramagnetic. 
The other important factor for the T1 performance of coated SPIONs is their dispersion state in 
colloidal solution. A small fraction of aggregation should drastically shorten the transverse relaxation 
time of the SPIONs because of increased dipolar magnetic interactions between them and thus 
compromise the T1 performance [37, 57].  
It has been shown that small-sized iron oxide-based nanoparticles with an overall diameter 
below 50 nm and core size of approximately up to 5 nm possess a potential to be utilised as high-
resolution T1-blood pool agents [58, 59, 61]. In vivo studies confirm their potential for MRI 
angiography. The most importance, in this case, is to extend their circulation time by ensuring full 
dispersion and long-term colloidal stability. The visualisation of blood vessels and vascular organs are 
demonstrated in Refs. [64-68].] 
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In the recent review by Shen et al. [65] the authors summarised liquid-based synthesis methods 
for production of magnetic iron oxide nanoparticles (MIONs) and extremely small magnetic iron oxide 
nanoparticles (ES-MIONs), and listed their applicability as T1 and T2 MRI contrast agents. The focus 
of the review is on the results for ES-MIONs (< 5 nm) and they are considered as the possible future 
generation of T1 MRI contrast agents, which avoid the both disadvantages of Cd-chelate-based T1- and 
MIONs-based (>10 nm) T2- contrast agents. 
The nanoparticles with bigger core size, however, could also act as an excellent positive 
contrast agent if good colloidal stability is observed, as it has been shown by Borase et al.[66]. The 
team prepared monodisperse galactose-coated SPIONs (core size 8.3 nm) with further potential for 
targeting, applying a novel combination of a polymer “grafting-from” approach with glycosylation by 
click chemistry. The as-prepared probes exhibit a very high r1 value of 16 mM
-1
 s
-l
 and although the 
r2/r1 ratio is 3.9 the T1-weighting potential remains because grafting-from/click-functionalization 
strategy provides a robust and adaptable chemistry that ensures optimal colloidal properties.  
The effect of coatings on the T1 performance of bigger SPIONs is also demonstrated in the 
recent work of Wan et al. [37]. The 8.5 nm SPIONs with narrow size distribution are synthesised by 
polyol process and further stabilised with sodium tripolyphosphate (STPP). For comparison, the same 
SPIONs are coated with sodium citrate. The polyanionic nature of STPP and its strong coordination 
capability to iron oxide warrant the SPIONs longterm colloidal stability (for years), while citrate-
capped SPIONs started to precipitate after several months. In addition, although the r1 relaxivity of 
STPP- and citrate-capped SPIONs are almost the same under a magnetic field of 1.41 T (18.88 and 
18.69 mM
-1
s
-1
), the r2/r1 ratio is different being of 3.87 and 6.55, respectively. Thus the minimised 
aggregation of the STPP-capped SPIONs successfully suppresses the T2 contrast effect, leading to 
optimised relaxometry properties for T1-weighted MRI, which is confirmed by in vivo tests with a 
mouse model. 
The composition of the nanoparticles used is another important parameter for achieving the T1 
contrast effect. Ling et al. [67] successfully visualised very small tumours (<3 nm) in mice via 
simultaneous pH-responsive T1 MR and fluorescence imaging, thus demonstrating the possibility for 
early stage diagnosis of tumours without using any targeting agents. These unique tumour pH-sensitive 
magnetic nanogrenades (PMNs) with a diameter of 70 nm are composed of self-assembled ES-MIONs 
(~ 3 nm) and pH-responsive polymeric ligands. For comparison, the pH-insensitive nanoparticle 
assemblies are also produced and studied. At neutral conditions, PMNs show high r2 relaxivity because 
of the clustering of nanoparticles, preventing an effective T1 contrast effect. The decrease in pH from 
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7.4 to 5.5 leads to slight increasing of r1 and significant decreasing of r2/r1 ratio only for PMNs, thus 
demonstrating their applicability for T1 MR imaging of acidic tumour regions. Moreover, it is 
established that accumulation of PMNs in tumours is >2-fold higher than that of pH-insensitive 
nanoparticle assemblies, and the team successfully perform in vivo pH-dependant photodynamic 
therapy to selectively kill cancer cells.  
In just available work of Zhang et al. [68] the correlations between the composition, size and 
MR T1 signal enhancement is investigated by comparison of MnFe2O4 nanoparticles with different 
sizes (2, 3, 3.9, 6) with Fe2O3 (3 nm), MnO (7 nm) and Gd-based contrast agents. Moreover, the authors 
report a general dynamic simultaneous thermal decomposition strategy to couple the multicomponent 
chemical doping process with the nucleation process, which allows controllable synthesis of 
monodisperse ultrasmall metal ferrites nanoparticles (< 4 nm) for highly sensitive and multifunctional 
T1 MR contrast agent. The procedure is suitable for large scale production of different kinds of metal 
ferrites nanoparticle MFe2O4 (M=Mn, Co, Ni, etc.). To achieve close decomposition temperature of Fe-
precursor and M-oleate precursors, the authors prepared a new type of Fe-precursor with improved 
thermal stability, namely Fe-eruciate. Further hydrophilization with phosphorylated mPEG do not 
affect the particle size. The obtained by this procedure ultrasmall MnFe2O4 nanoparticles exhibit very 
high r1 value, and the highest one of 8.43 mM
-1
s
-1
 is the highest measured among the ferrite 
nanoparticles with similar size reported so far, while the r2/r1 ratio is the smallest one. In contrast, the 6 
nm MnFe2O4 cannot be used for T1 imaging because of the high r2/r1 ratio of 46.1. In comparison with 
7 nm, MnO and 3 nm Fe2O3 the as-synthesised ultrasmall MnFe2O4 nanoparticles possess better MR 
relaxation properties for positive contrast effect. In vivo, MRI imaging of blood pools and liver showed 
their better properties than Gd-based contrast agents and verified that the ultrasmall MnFe2O4 
nanoparticles could be used as ultra-sensitive and multifunctional T1 MR contrast agents for high-
resolution MR imaging. The pharmacokinetic, biodistribution and excretion of the 3 nm UMFNPs 
indicates the safe of the UMFNPs for possible clinical trials. 
As was shown above the small-sized iron oxide-based nanoparticles can be effective T1 contrast 
agents. In the in vivo T1-weighted magnetic resonance imaging, they showed longer circulation time 
than the clinically used Gd-based contrast agent, enabling high-resolution imaging. Also, comparative 
studies on the toxic effects and tissue damage induced by three T1 MRI contrast agents – clinically used 
Gd-based contrast agent, ES-MIONs (3 nm) and MnO-NPs (15 nm) demonstrate that extremely small 
iron oxide nanoparticles exhibit better safety profile and more desired properties than the others [69]. 
The low toxicity, high r1 relaxivity, long blood half-life, low synthetic cost and possibility for further 
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functionalization enable SPIONs to be competent T1 for MRI contrast agents for various for clinical 
applications including diagnosis of the myocardial infarction, renal failure, atherosclerotic plaque, 
thrombosis, and angiogenesis of tumour cells.  
2.1.2. T2/T2* MRI contrast agents  
Even though iron oxide nanoparticles marked both the longitudinal and transverse relaxation 
processes, their effect on T2 relaxation is much greater than on T1 relaxation because their strong 
magnetic fields cause a rapid dephasing of the nuclei, resulting in apparent signal attenuation. The high 
r2/r1 ratio considered SPIONs as typical T2 contrast agents. Based on their biocompatibility and 
powerful effects on T2 relaxation, some formulation of developed SPIONs have been clinically 
approved as MRI contrast agents and suggested as a platform for synthesising materials that unify 
targeting, tracking, and hyperthermia treatment capability. To improve the performance of iron oxide 
nanoparticles the magnetic properties have been tunned by the modulation of size, shape and 
composition or by clustering. 
 The dependency of the r2 relaxivity on the nanoparticles size is evaluated and described in 
details with different approaches. When the size of nanoparticles increases, three different regimes of r2 
values exist, based on theoretical studies of the effect of size on relaxivity, which are explained in the 
reviews of Lee et al. [70] and Zanganeh et al. [71] - motional average regime (MAR), static dephasing 
regime (SDR), and echo limiting regime (ELR). Size in the MAR, SDR and ELR have been predicted 
by the quantum mechanical outer sphere theory [72-74]. In the MAR mode [75. 76], the relaxivity r2 is 
given by Eq. (2) [81], where all of the nanoparticles were approximated and simulated as a model of 
spheres:  
1/T2  =  (256π
2γ2/ 405)V*Ms
2α2 / D(1 + L/α)            (2)     
In the Eq. (2) γ is the proton gyromagnetic ratio, V*, Ms, and α are the volume fraction of the 
iron oxide core, saturation magnetization, and the radius of iron oxide core, respectively, D is the 
diffusivity of water molecules, and L is the thickness of an impermeable surface coating. 
For example, for spherical and quasispherical SPIONs with different coatings, the increasing of 
size in the range of 3 to 16 nm leads to increasing of r2 relaxivity from 2-fold up to approximately 20-
fold [39, 78, 79]. The same is shown by Mohapatra et al. [80] for citrate coated octahedral USPIO with 
average diameter of 6, 8 and 12 nm and for encapsulated within polyethyleneimine (PEI) nanorods with 
core size ranging from 30 to 70 nm and high r2 values in the interval of 312 to 608 mM
−1
 s
−1
, 
respectively. Also, the increase of Ms value with the size increase is also observed for the described 
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systems above. When the r2 relaxivity of the nanoparticles does not increase as the size does, the 
regime is called static dephasing regime (SDR) [81-83]. In SDR, nanoparticles create a magnetic field 
so strong that the T2 relaxation process is barely affected by diffusion. Accordingly, it is predicted that 
a plateau of the maximum r2 would appear. An example is water dispersible ferromagnetic iron oxide 
nanocubes encapsulated in DSPE-mPEG [84]. The increasing of core size from 22 to 28 nm leads to 
very slow decreasing of transverse relaxivity from 761 to 745 mM
-1
s
-1
. However, a further size 
increasing to 32, 42 and 49 nm leads to an abrupt reduction of r2 values to 532, 343 and 296 mM
-1
s
-1
, 
respectively, and gaining more valuable leads to the aggregation of the nanoparticles. When the r2 
relaxivity decreases as the size increases the regime is called echo-limiting (ELR) [85]. The effect of a 
decline of the r2 depends on the echo time, which is the time interval of the RF pulse that refocuses the 
nuclei spins. The nuclei spins are dephased when nanoparticles are too large; the fewer spins are 
refocused by the echo sequence, leading to decrease in the r2 and the further aggregation, due to the 
ferrimagnetic dipole interactions.  
A strategy to tune magnetic properties and to achieve a high transverse relaxivity is obtained by 
changing the shape of iron oxide nanoparticles, which affects the orientation of magnetic moments 
inside the particles as well as the dipolar interaction between IONPs. In a series of works different 
anisotropic IONPs (cubes, octahedras, disks, rings, octopod-like, rods) have been explored [34, 84, 90-
96].
 
In comparison to spherical shape IONPs they are found to be more appropriate for MRI and 
hyperthermia applications because shape anisotropy offers higher surface area, larger effective 
diameter and induces localised magnetic field inhomogeneity around the particles. In the following 
sections, we provide an example of the recent studies of Mohapatra et al., listed below. In Ref. [90] the 
team reports that 12 nm octahedral citrate coated USPIO with a core size of 12 nm exhibit higher 
relaxivity and specific absorption rate (SAR) than similar sized conventional spherical nanoparticles 
and commercial SPIONs. Increasing of core size from 6 to 12 nm leads to linear increasing of Ms 
values from 71 to 82 emu g
-1
, r2 values from 198 to 353 mM
-1
s
-1
 and SAR values from 163 to 275 W g
-
1
. In another recent work, Mohapatra et al. [80], propose a simple two-step reaction strategy for 
obtaining of encapsulated within polyethyleneimine Fe3O4 nanorods with a controllable core size of 30, 
40, 50, 60 and 70 nm and excellent r2 values of 312, 381, 427, 545 and 608 mM
−
1 s
−1
, respectively. 
These values are much higher than those obtained for spherical IONP with similar material volume, 
being of 141 to 297 mM
−1
 s
−1
 for 4 and 16 nm in size, although the last demonstrate higher 
magnetisation saturation. In the just-published paper, Beg et al. [34] show that porous single core 
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Fe3O4@SiO2 nanorods of 520 nm length and 180 nm diameter reveal two-fold higher transverse 
relaxivity (~192 mM
−1
s
−1
) in comparison with commercial contrast agents. Also, the authors 
demonstrate their applicability as multifunctional nanoplatforms for magnetic theranostics. Although 
the promising reports for potential bioapplicability of anisotropic NPs, their advantages have not been 
well demonstrated in the literature because of challenges for their preparation, which have to 
accomplish the requirements for excellent shape and size control which means high reproducible 
production process. 
Another method for improving the performance of SPIONs as negative contrast agents is by 
applying clusters of nanoparticles. In a very recent paper, Smith et al. [91] report how to control the 
self-assembly of SPIONs into worm-like superstructures using glycogen-like amphiphilic 
hyperbranched polyglycerols (HPGs) functionalized with peptides capable of binding to the defective 
vasculature. The SPIONs worm-like clusters possess a 3.5-fold higher T2-weighted MR relaxivity than 
conventional SPIONs. According to the authors, the design principles exposed for these nanoprobes 
should be expanded to a range of different proper moieties for refining the diagnostics of other 
diseases. In recent work of Chen et al. [92] the team developed very stable nanoclusters of SPIONs 
with a controlled clustering structure using SPIO nanocrystals of size 8 nm and alkyl-modified 
polyethyleneimine. The advantages of the self-assembly of SPIO nanoclusters for universal cell 
labelling with MRI monitoring capability are presented. The nanoclusters show excellent performance 
on cellular uptake and cell labelling in a different type of cells, which are tracked by MRI with high 
sensitivity.  
Many studies have been performed to investigate the MRI contrast efficiency of SPIONs and 
the effect of coatings in in vivo scenarios. The coating determines the overall size, stability and 
circulation lifetime of the nanoformulations, their distribution and fate in the organism, degradability 
and relaxivity. An example how optimisation of coating type and thickness could lead to high contrast 
in vivo imaging are shown in the works of Saraswathy et al. [93, 94]. The SPIONs with the same core 
size of 12 nm are coated with citrate or high molecular weight dextran. The coating thickness is 
optimised to achieve high r2/r1 ratio, being of 37.92 for 30 nm citrate coated SPIONs and 56.28 for 50 
nm dextran coated SPIONs. The probes are used for MR imaging of liver fibrosis of male Wistar rats 
after injection of 2.17 mg/ml Fe/kg body weight. The post contrast T2 weighted images 5 min after 
administration showed a hypointense liver with 39% and 55% decrease in the average MRI signal 
intensity for citrate and dextran coated SPIONs, respectively. The results indicate a higher 
hepatocellular uptake of dextran-SPIONs. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
16 
 
In recent work of Mishra et al. [95] 13 nm low molecular weight dextran coated USPIO 
nanoparticles (r2/r1 ratio of 4.92) are investigated for tumour detection, organs and whole mice body 
imaging. The signal started to drop remarkable in 1 hour after injection of nanoparticles (3.0 mg Fe/kg 
body weight), which continued up to 48 h, thus facilitating the distinction. For kidney and heart 
imaging maximum contrast is achieved at 24 h, while for solid tumours the maximum contrast is 
evident after 48 h. 
Uchiyama et al. [96] prepared ethylamine-functionalized cationic USPIOs with high and lasting 
negative MRI contrast effect in the liver imaging of male Wistar rats and insignificant acute toxicity. 
The in vivo and ex vivo monitoring of nanoparticles biodistribution and dose effect (10 vs. 50 mg/kg) 
on clearance behaviour are investigated. The results showed that nanoparticles circulate freely 
throughout the vascular system, retent only in the liver, kidneys and bladder, and clearance process is 
dose-dependent. 
Xie et al. [97] considered the impact of surface functionality and surface zeta potential on the 
contrast efficiency for in vivo vascular MR imaging of mouse brains, comparing 20 nm PEG/SPIONs-9 
nm, 21 nm PEG/PEI coated SPIONs-10 nm and 24 nm Tween 80 coated PEG/PEI/SPIONs with dzeta 
potential of -5, 35 and 19 mV, respectively. All of the samples are with high r2/r1 ratio (up to 86.66) 
due to the anisotropic shapes of the core. After injection in Kunming mice (dose: 10 mg Fe/kg) all 
nanoprobes showed enhanced and long-lasting (24 h) T2* MRI contrast effects in the mouse brains 
after 24h intravenous injection of the nanoparticles. However, the PEG/SPIONs exhibited stronger 
contrast-enhanced T2* imaging effects than the others (especially in the first 30 min) and caused 
stronger reducing in T2* values at different locations of the brain, implying that PEG/SPIONs were 
cleared more slowly by the mononuclear phagocytic system than the others.  
In the study [98] Cano et al. apply the ligand-exchange method and amine-silane derivative 
triethoxy-silane (APTES) to produce hydrophilic 96.8 nm SPIONs with better structural stability, 
although with poor colloidal stability. To improve the previous outcomes, the authors applied partial 
PEGylation of silanized SPIONs [99]. They obtained that 47.6 nm ultrastable hydrophilic NPs have 
virtually no cytotoxicity and under a magnetic field of 1.5 and 9 T reveal a high r2 value of 121.56 and 
98.74 mM
-1
s
-1
, and a high r2/r1 ratio of 50.65 and 93.15, respectively. An excellent T2 contrast in vivo 
imaging of the liver and the spleen is observed 1 hour after injection in female BALB/c mice even at 
the lowest dose (11mg Fe/kg). Moreover, it was shown that partial PEGylated SPIONs could be 
functionalized further by residual surface reactive amine groups offering a tunable platform for the 
development of smart diagnostic and therapeutic nanosystems.  
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Particular attention has to be paid to the work of Richard et al [38] devoted to the synthesis of 
size tunable USPIO for neoangiogenesis T2 MRI contrasting.  The team proposes to control the USPIO 
size to optimise MRI T2 relaxation times, and neovascularization is targeted through the enhanced 
permeability and retention (EPR) effect. Using a nonaqueous sol-gel method assisted by microwave 
heating the USPIO nanoparticles with sizes 3, 6 and 9 nm are produced and coated with polyethylene 
glycol phosphonate moieties. The 3 nm-sized USPIO has dramatically low r2 relaxivity whereas 9 nm-
sized exhibits high r2 value close to 200 mM
-1
s
-1
. An ischemia-reperfusion rat model has been chosen 
for neo-angiogenesis. Although 6 nm nanoparticles had a lower relaxivity than the 9 nm ones, the in 
vivo experiments show that the sharpest signal decrease is obtained for 6 nm USPIO, due to their better 
vascular circulation. Thus, the team demonstrates that the controlled nanoparticles size and the PEG 
passivation reduce the RES clearance, enhance their blood circulation time and permit ischemia 
targeting through the enhanced permeability and retention (EPR) effect. 
The combination of nanoparticles with liposomes is an approach which is proven as an 
extremely elaborative in the fields of nanomedicine and nanobiotechnology. When liposomes 
encapsulate iron oxide nanoparticles the general term ‘magnetoliposomes’ (MLs) is used for the 
resulting colloidal structures [100]. MLs have been used as contrast agent for molecular imaging and as 
a theranostic tool [101-103], but mainly as an efficient MRI contrast agent with enhancing T2 contrast 
[104] – Fig. 3 
 
Fig. 3. First line: MRM axial image of the first echo for the aqueous phantom and for the SPC sample, 
respectively. Second line: MRM axial image of the 30 order echo, for the aqueous phantom and for the 
SPC sample, respectively - Reproduced from [104] with permission from the ELSEVIER. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
18 
 
Classical and extruded are two kinds of MLs depending on their structure. In the classical MLs, 
each iron oxide nanoparticle is surrounded by a bilayer of phospholipids. This kind of MLs was first 
prepared by De Cuyper et al. [105]. Different types of phosphatidylglycerols are used to form the 
liposomes. The whole size of the MLs is around 20 nm. For the preparation of classical MLs, magnetite 
nanoparticles were first stabilised with lauric acid and then sonicated phospholipid dispersions were 
added to the magnetite suspension. The second type extruded MLs, in which inside the lipid bilayer 
there are several iron oxide nanoparticles, they can act as an efficient MRI contrast agent with 
enhancing T2 contrast. For these MLs, the ratios of the transverse and longitudinal magnetic resonance 
are between 6 and 18 mM
−1 s−1, which positions them among the best T2 contrast agents. These MLs 
have been targeted successfully to solid tumours, and they led to a 52% contrast enhancement in the 
magnetically targeted tumour, while there was only 7% improvement in the nontargeted tumour [106]. 
In the work of Martínez-González et al. [107], the authors proposed sonication process applied to MRI 
response of hydrophobic or hydrophilic SPIONs loaded into MLs of different lipid composition. 
Liposomes were made of six formulations, differing in the fatty-acid chain length, the presence or 
absence of cholesterol (CHOL), and the presence or absence of negative charge (afforded by 
phosphatidylserine, (PS)). The relaxivity properties of such hybrid nanoparticles after sonification were 
determined at 7 T. The contrast is enhanced, and high values of r2 are obtained when the hydrophobic 
nanoparticles are used. 
In the work of Barbara et al. [108] the authors developed a new long circulating MLs which can 
be utilised as an MRI negative contrast agent for detection of liver ischemia–reperfusion injuries. The 
MLs are formed by encapsulation of a SPIONs covered with polyethylene glycol (PEGylated SPIONs) 
and were prepared by the dehydration–rehydration method followed by extrusion. In Fig. 4 is depicted 
a model of MLs formed by the encapsulation of a SPIONs suspension in a liposome is depicted. The 
MLs relaxivities r1 and r2 showed a minor effect on T1 but a major effect on T2. Thus the effectiveness 
as negative contrast agents of long circulating magnetoliposome, over approved clinical contrast agents 
such as Endorem and Sinerem, is proven. 
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Fig. 4. Model of MLs formed by the encapsulation of a SPIONs suspension in a liposome. 
 
 
 
 
2.1.3 Dual T1 – T2 
The T1–T2 dualmodal strategy for MRI has attracted considerable interest because it can give 
highly accurate diagnostic information by the beneficial contrast effects in both T1 imaging with high 
tissue resolution and T2 imaging with high feasibility on detection of a lesion. Therefore, simultaneous 
achievements of positive and negative contrasts have been extensively followed to obtain 
complementary information on T1-weighted MRI and T2 -weighted MRI [109,110].   
The application of the potential of SPIONs as a T1 MRI contrast agent has been identified in the 
work of Chan et al. [111], where the size of SPIONs should be optimum (<5 nm) to achieve good T1 
contrast effect. Moreover, both T1 and T2 relaxations can be enriched in a single iron oxide nanoparticle 
by optimising their size, shape and surface coatings.  
In an investigation of Zhou et al. [112] is shown that superparamagnetic nanoplates with (111) 
exposed facets have significant but interactional longitudinal and transverse relaxivities. By controlling 
structure and surface features, including morphology, exposed facets, and surface coating the authors 
demonstare that balance of T1 and T2 contrasts can be regulated. 
In another investigation Ghobril et al. [113] showed that the dendron-modified SPIONs indicate 
better T1 and T2 contrasts, compared to commercial SPIONs used for MRI contrast [114, 115].  
A simple way to construct T1–T2 dual-mode contrast agents is the conjugation of T1 elements 
(e.g. Gd- or Mn-based chelates) and T2 elements, as shown in the other work of Zhou et al. [116]. They 
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tailored iron oxide nanoparticles by including paramagnetic metal ions, such as Gd
3+
 and Mn
2+
. The 
strong magnetic fields generated by T2 contrast materials dislocate the T1 relaxation processes, which 
results in a signal decrease. Therefore, the direct interaction of magnetic nanoparticles and 
paramagnetic ions should be avoided. Consequently, the separating layers, such as long PEG chains 
and/or silica shells, are required to control the magnetic coupling between T1 and T2 contrast materials. 
The r1 relaxivity is dramatically increased from 2.0 to 32.5 mM
−1
s
−1
, while the r2 relaxivity is 
ascetically decreased from 340 to 213 mM
−1
s
−1
 by increasing the thickness of the separating silica 
layer. [115, 117, 118]. In the Supplement information are summatised some results based on dual T1-T2 
modalities presented like Table 2.  
2.2. Combined Multimodal MR Imaging Agents – 
Multimodality molecular imaging is now playing an essential role in the biomedical research. 
Multimodality imaging is emerging as a technology that utilises the strengths of different modalities 
and yields a combined imaging platform with benefits superior to those of any of its individual 
components. The commonly used clinical imaging modalities include optical imaging, X-ray computed 
tomography (CT), MRI, positron emission tomography (PET), single-photon emission CT (SPECT) 
and ultrasound imaging (UI). The advantages and disadvantages of these diagnostic technics are 
described elsewhere [119-123]. 
For example, MRI and CT have high spatial resolution and can provide detailed anatomical 
information, but they lack sensitivity. The PET and SPECT enable high sensitivity of monitoring 
metabolic pathways and ligand-targeted information, but have limited spatial resolution and cannot 
provide anatomical information. The optical imaging (e.g. fluorescence) is a selective, high-contrast 
method, which provides real-time guidance, and the same time is less costly and widely available 
[124]. However, it had qualitative nature and limited tissue penetration. On the other hand, a relatively 
new photoacoustic tomography (a hybrid modality), based on the use of laser-generated ultrasound 
offers a deep tissue penetration [125]. The improvement of diagnostics or guidance can be reached by 
using two or more techniques simultaneously which can provide more accurate and reliable data than 
when single imaging modality is used through analysis of complementary, co-registered, and data-rich 
images [126]. For example, the first fused PET/CT instrument was available commercially in 
2001[127]. Moreover, the first commercial PET/MRI prototype was presented in 2007 [128]. For 
combined multimodal modalities, the use of multifunctional nanoparticles is crucial because the 
corresponding information can be provided with a single injection of functionalized contrast agent. The 
T1 and T2-contrast enhancement produced by SPIONs and the potentials for their functionalization with 
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radioisotope(s), biomarker(s), optical active molecule(s), drug(s) offer the opportunity to combine 
various modalities, such as PET/MRI, SPECT/MRI, PET/MR/optical imaging and etc. The strategies 
for engineering of magnetic nanoparticles and their ability in multimodal imaging are reviewed through 
the years, and some of the recently published works as follows [129-132].The examples given below 
are focused mainly on radiolabeled iron oxide nanoparticles 
The other exampales based on multimodal imaging probes on SPIONs are summarised in Table 2 
and presented in the Supplemental information section.  
A common approach for radiolabeling of SPIONs is to attach isotopes onto the surface through 
chelating ligands or by passive adsorption. However, the process and further purification are 
complicated and relatively slow, and the stability of chelated radionuclide in vivo is often undefined 
[133, 134]. In fact, other approaches are now being explored: incorporation of radioisotopes into the 
nanoparticle core and chelator-free labelling procedures 
99m
Tc or 
64
Cu labelled bifunctional bisphosphonate-based chelators (BP) were used by Rosales 
et al. [135, 136] to bind a PET isotope and inorganic surface of dextran coated SPIONs 
(Endorem/Feridex). The in vivo MRI - nanoSPECT-CT [135] and PET–MR [136] imaging revealed the 
bimodal imaging capabilities and excellent stability of these nanoparticles. 
89
Zr-labeled ferumoxytol 
(via coordination with desferrioxamine-DFO) was used for PET-MRI mapping of tumor-drained lymph 
nodes (LN) in mice [137].  
A highly specific chelator-free approach for labelling of SPIONs was presented by Chen et al. 
[138]. The PAA coated SPIONs were labelled with radioarsenic nuclides *As (*=71, 72, 74, 76) and 
PEGylated further for increasing theirs in vivo stability. The team presents also a chelator free method 
for 
69
Ge labelling of SPIONs [139]. The 
*
As-SPION@PEG and intrinsically labelled 
69
Ge- 
SPION@PEG nanoparticles were used for PET/MR dual-modality sentinel lymph nodes mapping. A 
new reaction for chelate-free, heat-induced metal ion binding and radiolabeling of USPIOs 
(ferumoxytol) was proposed recently by Boros et al. [140]. The authors demonstrated that high 
efficient labelling of metal-based nanoparticles with different isotopes, such as 
89
Zr, 
64
Cu, 
111
In could 
be achieved under the similar reaction conditions. 
89
Zr labelled ferumoxytol was tested for in vivo 
PET/CT imaging in mice and parallel for biodistribution. According to the authors, this chelate-free 
labelling method can be employed to facilitate clinical translation of a new class of multimodality 
PET/MRI radiotracers. 
A multi-step procedure for the chelate-free synthesis of 
68
Ga labelled nanorods for PET/T2-MR 
multimodal imaging was reported by Burke et al. [141]. Siloxane polyethylene glycol derivative was 
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used for obtaining of PEG-coated iron oxide nanorods, preliminary synthesised. The presence of silica 
allowed further chelate-free labelling with 
68
Ga due to the formation of Ga–O–Si bonds. The 
biodistribution was studied in vivo, and the stability of nanoradiotracers was proofed by in vivo and ex 
vivo analyses.  
A challenge to labelled SPIONs with short-lived radioisotopes in one-step procedure was 
overcome by Pellico et al. [142]. The authors reported extremely fast and reproducible microwave 
synthesis (MWS) which allowed production of dextran coated extremely small (2.5 nm) 
68
Ga core-
doped iron oxide nanoparticles with high radiolabeling yield. Also, the measured value for r1 relaxivity 
is greater than that of clinically approved Gd-based positive contrast agents. The team also 
demonstrated the likely use of these radiotracers by their further coupling with RGD peptide via a 
homo-bifunctional linker. The 
68
Ga-SPIONs and 
68
Ga-SPIONs-RGD were evaluated in murine 
angiogenesis model by PET-T1 weighted MR imaging. The biodistribution was monitored. It was 
established that presence of RGD peptide lead to accumulation in the tumour area of tumor-bearing 
mice and selectively integrin binding to angiogenic endothelial cells.  
The T1-weighted MRI-SPECT multimodal imaging was also shown in the well-known work of 
Sandiford et al. [60], based on 
99m
Tc labelled USPIONs. The in vivo tests reveal their potential for MRI 
angiography due to the long blood circulation time and high signal enhancement.  
99m
Tc labelled USPIONs, conjugated with c(RGD) peptide were obtained by Xue et al.[143] for 
dual-contrast (T1/T2) MR and dual-modality (SPECT-MR) imaging of tumour angiogenesis. 3.5 nm 
USPIONs were synthesised using polyol method, coated with COOH-PEG-NH2, further conjugated 
with cRGD and labelled with 
99m
Tc (via chelator). The measured r1 value is higher than that of 
clinically approved Magnevist. The biodistribution in vivo and ex vivo were monitored. It was 
established that the nanoplatforms retained mainly in the liver, spleen and stomach. The tumour 
accumulation of 
99m
Tc-USPION-RGD was also significant.  
Dual-mode agents for ultrasound imaging and MRI are the object of interest in recent years 
[144-148].  Microbubbles (MBs) with a gas core that is stabilised by a shell prepared of proteins, lipids, 
or polymers are typically ultrasound contrast agents.  
In the work of Sciallero et al. [149] to the external surface of polymer-shelled MBs were 
anchored with different densities of superparamagnetic iron oxide nanoparticles or like a second 
scenario were physically entrapped into the shell. Under selection of a proper condition, set-up 
parameters and variation in the SPIONs densities satisfactory detection of the contrast agent by using 
both UI and MRI was achieved. When the SPIONs density was increased, the MRI contrast improved, 
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while the UI contrast worsened due to the reduced elasticity of the MB shell. The MBs with SPIONs 
which are externally anchored provided improved performance than MBs entrapped into the shell 
SPIONs for both UI and MRI.  
 In the study of Teraphongphom et al. [150], the authors developed MBs by encapsulating 
nanoparticles including aqueous or organic quantum dots (QD), magnetic iron oxide nanoparticles or 
gold nanoparticles (AuNP) to create bimodality platforms in a manner that minimally compromised the 
performance of each imaging technique. 
In the work of He et al. [147], they described the MBs ability to enhance UI and MRI image 
contrast. In this study, the authors synthesised MBs with a novel structure, which included a nitrogen 
gas core, a polymer shell, and SPIONs on the shell surfaces. The MBs with such structure applied to in 
vitro experiments provided both higher UI and MR enhancement than blank MBs without SPIONs and 
previously designed microbubbles where the SPIONs are embedded. Figure 5 represents the SEM and 
TEM characterization of microbubbles. SEM images showed that all microbubbles were spherical. 
Blank MBs surfaces were the smoothest, and SPIO-embedded MBs surfaces were coarser. TEM 
images showed the distributions of the nanoparticles. No nanoparticles could be observed from blank 
microbubble. On SPIO-coated microbubble's surface nanoparticles were randomly distributed, but for 
SPIO-embedded MBs, the nanoparticles were mostly distributed in the shell, and only a small number 
were adsorbed on the surface (Fig. 5). 
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Fig. 5. SEM images of (a) blank microbubbles, (b) SPIO-coated microbubbles, (c) SPIO-
embedded microbubbles, TEM images of (d) blank microbubble, (e) SPIO-coated microbubble, (f) 
SPIO-embedded microbubble, (g–i) are partially enlarged images of (d–f). Reproduced from [147] with 
permission from the ELSEVIER.  
The authors conclude that some SPIONs-loaded MBs have been developed as contrast agents 
for UI/MR dual-modality imaging investigations. However, the disadvantage of such type of UI/MRI 
contrast agents were reported like a low degradation in the body [151, 152]. A contrast agent for 
UI/MRI dual-modality imaging with biodegradable multifunctional nanoscale particles is desired, and 
the number of such systems is increasing in the last years. The group of Yang et al. [153] developed a 
new class biodegradable yolk-shell magnetic microspheres for UI/MRI dual-modality imaging. The 
nanosystem contains a magnetic core of Fe3O4 nanocluster stabilised by poly(γ-glutamic acid) (PGA) 
and functional shell of disulphide cross-linkage biodegradable poly(methacrylic acid (PMAA). The 
authors handled perfluorohexane (PFH) like an ultrasound-sensitive object into the inner cavities of 
yolk-shell microspheres to gain ultrasound imaging signal.  The yolk-shell microspheres attend as 
perfect contrast agents for UI/MR dual-modality imaging. The entire process of fabricating 
biodegradable Fe3O4@PMAA microspheres is demonstrated in Fig. 6.  
 
Fig. 6. (a) Schematic illustration of the preparation of uniform biodegradable yolk-shell Fe3O4@PFH@PMAA-
DOX  microspheres; (b) Schematic setup for US and MRIdual-modality imaging and drug delivery system using 
Fe3O4@PFH@PMAA-DOX  microspheres. Reproduced from [153] with permission from the ELSEVIER.  
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The review stresses on the MLs like another object that can serve as a multimodality contrast 
agent. The flexible nature of the ML coatings, together with the simple production procedure, allows 
fast and easy modification of the surface and offers many exciting applications as multimodal contrast 
agents. In the recent work of Malinge et al. [154], they describe a new liposomal formulation enabling 
PET and magnetic resonance MR imaging. Compared to other protocols outlined in the literature [138, 
155], the proposed process by the team of Malinge is rapid and simple to use in clinical and preclinical 
laboratories practice. The bimodality is achieved by coupling 
68
Ga-based radiotracer on the magnetic 
liposomes bilayer. The two new phospholipids were synthesised, 
68
Ga (DSPE-PEG-NODA) with a 
specific chelator and the second (DSPE-PEG-NODA-Glu) with a glucose moiety. The liposomes were 
produced according to a fast and safe process with a high radiolabeling yield. MR and PET imaging 
were performed on mice bearing human glioblastoma tumours (U87MG) after in vivo injection. The 
MR and PET imaging is created by the accumulation of the liposomes in solid tumour. 
To achieve more accurate diagnosis in vivo much comprehensive information is required, so the 
interest in developing of nanoprobes for tri and higher mode imaging is grown in the latest years. The 
examples for PET, SPECT-MRI-optical multimodal imaging could be found elsewhere in the literature 
so that we will focus on the recent examples with other modality– photoacoustic tomography (PAT). 
PAT is a relatively new hybrid modality with potential for several clinical applications, including 
imaging of cancer [156] and vasculature [157]. With deep tissue penetration PAT is excellent 
complementary imaging techniques for PET and also could be combined with photothermal imaging 
(PTI). 
 Double-PEGylated reduced graphene oxide (RGO) nanosheets anchored with iron oxide 
nanoparticles and labelled with 
64
Cu via NOTA-chelator were used for PET-MR-PAT imaging [158]. 
The nanoconjugates obtained exhibited a high stability due to the second PEG-layer, prolonged blood 
circulation half-life and remarkable tumour accumulation. PEGylated 
64
Cu-MoS2-IONPs were 
developed and tested in vivo for triple-modal PET-MRI-PAT imaging-guided cancer therapy [159]. 
The efficient tumour retention of nanoradiotracer was established and the conducted photothermal 
therapy showed an effective tumour ablation. The synergetic benefit of multimodality by providing of 
imaging-guided photothermal therapy was also demonstrated by Lin et al. [160]. The authors reported 
an innovative procedure for obtaining of new type IONPs-based contrast agents (magnetic melanin 
nanoparticles) and their labelling with 
64
Cu by biomimetic synthesis method. The possibility of the 
prepared nanoparticles to serve as a versatile biomimetic theranostic agent for PET-MR-PAT-PT 
multimodal-imaging-conducted cancer photothermal therapy was shown. 
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The magnetic nanoparticle-based multimodal imaging approaches hold the new capacity to 
sheltered enhanced imaging sensitivity and precision for a better understanding of biological systems 
and accurate imaging of biological targets.  
2.Therapeutic platform based on magnetic nanoparticles - 
2.1.Magnetothermal Treatment 
Although the magnetothermal effect values of SPIONs increase as the frequency (f) and/ or the 
amplitude (H) of the magnetic field increases, it is recommended that the product of the frequency and 
the amplitude (Hf) should be smaller than 5 × 10
9
 A m
−1
 s
−1
 for the safety of patient [161, 162]. For 
example, Megaforce's NanoTherm therapy, which has been approved in Europe for the treatment of 
brain tumours, uses the magnetic field at a frequency of 100 kHz and field amplitudes in the 2−15 kA 
m
−1
 range where the product Hf is below the threshold [163]. Significant efforts are devoted to 
maximising heating efficiency (i.e., excellent SLP) of nanoparticles in a given frequency/amplitude of 
magnetic field and to improve an external magnetic field setup that generates a focused AMF.
 
In a 
traditional magnet configuration, magnetic nanoparticles dispersed in any tissues including normal 
tissues are equally heated because AMF is nonselectively applied inside the solenoid. This unwanted 
and non-selective heating is the most serious shortcoming in this type of technique. Recent studies on 
the application of a static magnetic field show the potential of AMF focusing [164, 165]. The focusing 
position can also be changed by giving different amplitudes of direct current to the solenoids.  
Temperature measurements with high resolution and accuracy are critical in nanoparticle-based 
thermal therapeutic applications [166, 167]. The optical method is of substantial importance to quantify 
magnetic nanoparticles local temperature [168-172].  
Magnetic nanoparticles linked with fluorescent dyes such as a DyLight549 fluorophore or 
coated with a thermoresponsive fluorescence polymer such as poly(N-isopropylacrylamide-fluorescent 
modified acrylamide) (pNIPAM-co-FMA) changes their fluorescence intensity depending on the 
surrounding temperature. Absolute temperature detection is also possible. In a study with maghemite 
nanoparticles coated with rare earth metal chelates (e.g., Tb
3+
 and Eu
3+
) in a silica shell was found that 
the emission from Tb
3+
 chelates is temperature-dependent, while that of Eu
3+
 chelates remains constant 
for the same temperature region. The determination of the ratio of Tb
3+
 over Eu
3+
 emission allows the 
absolute temperature measurement. In another study [171] subnanometer scale temperature gradient 
profile versus the distance from the surface of the magnetic nanoparticles was demonstrated by a 
thermolabile azo-linker, 2,2′-azobis[N-(2-carboxyethyl)-2-methylpropion-amide], functionalized with 
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fluorescein amine. Another similar example is the utilisation of a rigid DNA double helix structure 
[170]. The 12 nm core iron oxide nanoparticles stabilised with 2 nm thick amphiphilic polymer are 
conjugated with single-stranded DNA and subsequently hybridised with fluorophore-modified DNA 
having lengths of 3.0, 3.3, and 3.6 nm, each with different melting temperature. After AMF application, 
local temperatures at three different distances from the surface of the nanoparticles (i.e., 5.0, 5.3, and 
5.6 nm) are determined by correlating the denaturation profiles of the DNA.  
Despite the satisfactory spatial resolution, high-cost and the requirement of significant facility 
investment are limitations. That is why ultrasound seems to be an alternative imaging temperature 
monitoring due to the low price and positive response [173]. Among others, attenuation is known to be 
one of the most promising parameters and has been widely used in ultrasound thermometry. 
Attenuation is the amount of energy lost due to the reflection, scattering, or absorption of energy when 
ultrasound passes through a medium. Many studies have shown that the attenuation rate increases at 
high temperature. 
 
2.2.Thermal Ablation.  
Exposure to high temperature above 50 °C causes cancer cell death [166, 167]. The application 
of magnetic nanoparticles seems to be an acceptable alternative due to their perspective properties. 
Once the magnetic nanoparticles are administrated, the nanoparticles can be preferentially accumulated 
at the tumour site. Therefore, the concurrent external magnetic field application can ablate the tumour 
in a remote and noninvasive manner. One in vivo animal feasibility test was carried out using human 
breast adenocarcinomas-implanted immunodeficient mice [174]. After intratumoral injection of iron 
oxide nanoparticles, the mice are exposed to an AMF for 4 min (amplitude 6.5 kA m
−1
; frequency 400 
kHz). In the experiment the temperature is increased up to 73 °C. Histologic tests indicate early stages 
of coagulation necrosis in the tumour tissue. Indeed, these nanoparticles can create a localised hot spot. 
It could kill tumour cells. However, the poor energy-transfer efficiency of the iron oxide nanoparticles 
(i.e., low SLP) as a mediator presents could leave to serious problems. In the work of Lee et al. [175] 
the authors developed a core−shell magnetic nanoparticle, CoFe2O4@MnFe2O4, with a very high SLP 
of 2280 W g
−1
(magnetic atom). A small amount (75 μg) of 15 nm CoFe2O4@MnFe2O4 nanoparticles 
dispersed in normal saline (50 μL) are injected into a U87MG human brain tumour (100 mm3) in mice; 
then, an AMF of 500 kHz at 37.3 kA m
−1
 is applied for 10 min. After 18 days, the tumour treated with 
the core−shell nanoparticles is eliminated. For the case of treated mice with Feridex possessing low 
SLP of 115 W g
−1
(magnetic atom), the tumour size increases by 9-fold in 18 days and its growth behaviour 
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is similar to that of the untreated control mice group. Initially, the tumours show a stage of regression 
(for the doxorubicin-treated group), but they recover in a much larger size.  
 
2.3. Apoptotic Hyperthermia.  
Although the use of thermal ablation has the advantage of quick tumour removal, the 
surrounding healthy tissues are possibly damaged and cannot be preserved at the high temperatures 
needed to kill the surrounding cancer cells. A lower-temperature window between 42° and 45°C can 
offer the possibility of destroying the cancer cells preferentially [176, 177], which is called 
hyperthermia [163, 178] - (Fig. 7). A temperature below 45°C induces apoptotic cell death, which is a 
more benign form of the “programmed” cell death compared to necrosis [1179, 180]. Phagocytosis 
removes cells dying during the apoptosis without impact on the neighbouring healthy cells [181, 182]. 
Many magnetic nanoparticles, including Fe2O3 coated with stabilisers and Fe3O4 encapsulated in 
cationic liposomes, have been tested for magnetic hyperthermia and this form of hyperthermia is 
clinically approved in Europe for the treatment of glioblastoma [183]. 
 
Fig. 7. Therapeutic strategy using magnetic particles - hyperthermia 
If superparamagnetic nanoparticles are considered, many approaches for magnetic 
hyperthermia, which is self-controlled heat mediator based on ferromagnetic nanoparticles with 
optimised Curie temperature (Tc) could be cited [18-190]. 
As known, magnetic materials could change magnetic properties above Tc and it prevents the 
conversion of electromagnetic energy into heat. Therefore, Tc appears to be the maximum temperature 
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which magnetic nanoparticles could reach. Controlling Tc can be an effective way to prevent 
overheating.  
Recent studies show ways to improve the magnetic hyperthermia efficacy, and the first approach 
is targeted intracellular hyperthermia. Surface epidermal growth factor receptors (EGF) in cancer cells 
were targeted by carboxymethyldextran-coated iron oxide nanoparticles conjugated with EGF. If the 
intracellular hyperthermia effect is recorded at different specific absorption rates (SAR), it could be 
observed that at a high SAR, the survival factor of cancer cells treated with the magnetic nanoparticles 
and magnetic field decreases by 0.06% without a noticeable rise in temperature [191]. Another example 
is the folic acid (FA), and PEG-functionalized superparamagnetic nanoparticle clusters (FA-PEG-
SPION NCs) [192]. The FA-PEG-SPION NCs, produced via the thiolene click reaction between allyl-
SPIONs and thiol of FA-functionalized PEG, are intravenously injected, and AMF (8 kA m
−1
, 230 
kHz) is applied to tumor-bearing mice to inhibit tumour growth significantly. 
DeNardo et al. [193] proposed an approach which demonstrated for heat shock protein (Hsp) 90 
targeted hyperthermia. The thermal tolerance is related to Hsps, known to protect cells from apoptosis. 
In the experiments, geldanamycin (GM), known as Hsp90 inhibitor, is combined to 15 nm Zn0.4Fe2.6O4 
nanoparticles by thermosensitive 4,4′-azobis(4-cyanovaleric acid).The magnetic nanoparticles generate 
the heat necessary for MDA-MB-231 cancer cell death and also release GM by thermal cleavage of the 
azo bond in the presence of an AMF. The released GM efficiently blocks Hsp90’s chaperonic function 
in cell survival, and the efficiency of hyperthermia-mediated apoptosis is significantly enhanced. While 
the conventional magnetic hyperthermia at 43°C for 80 min induces only 25% cell death, this newly 
developed magnetic nanoparticle system significantly increases the cell death to 89% in 60 min and 
completely removes all the cancer cells in 70 min. In vivo efficiency of this method is also validated 
where the breast cancer xenografted in mice is completely removed with the GM-linked magnetic 
nanoparticles, while the conventional magnetic nanoparticles show a 2.5-fold increase in the tumour 
volume on day 14 after a single hyperthermia treatment. 
The magnetic nanoparticle-based thermal treatment possesses serious advantages due to the 
possibility for synergistic combination with treatments like chemotherapy, radiation therapy, gene 
therapy, and photodynamic therapy. For instance, hyperthermia combined with radiation or gene 
therapy is more effective than either hyperthermia or radiation/gene therapy alone because of the 
complementary mechanisms of cell death. One good example is the application of 20 nm dextran-
coated iron oxide nanoparticles in the treatment of prostate cancer [194]. The exposure of the 
nanoparticle-treated cancer cells to AMF followed by radiation results in a significant cell death. 
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Another example is 23 nm ZnFe2O4 magnetic nanoparticles complexed with lethal-7a miRNA using 
branched PEI via a layer-by-layer approach.  
Through the increased retention of the magnetic nanoparticles in the tumour sites the antibody-
labeled magnetic nanoparticles show enhanced efficacy as a result of tumour targeting, magnetic 
hyperthermia, and radiation, therapy and chemotherapy for the therapeutic efficacy enhancement. 
 
3. Magnetic hyperthermia therapy 
Hyperthermia therapy (HTP) is a heat induced malignant cancer treatment where SPIONs serve 
as heat producers. To provoke a treatment effect SPIONs are introduced near to the cancer tumour 
location by the use of magnetic targeting. An alternating magnetic field (AMF) is applied for a 
specified period to produce heat for initiating apoptosis in cancer cells. Optimal results could be 
achieved by controlling the size, shape, crystallinity, magnetic properties of SPIONs and parameters of 
the applied AMF. The effect of the therapy is assessed by the specific absorption rate (estimate of the 
conversion of the AMF into heat) Cervadoro et al. [195] reported that the relaxations required for 
inducing heat from SPIONs (5, 7 and 14 nm sized) started to take place at a frequency range i.e. less 
than 1 MHz and ending above this frequency range when tested for wide range of frequencies (up to 30 
MHz). In a similar fashion as reported by Lartigue et al. [30], multicore magnetic nanoparticles 
exhibited high SAR value of almost 2000 W g
-1
 (applied field of 29 kA m
-1
 and frequency of 520 kHz) 
with an increase in temperature rate of 1.04
°
C s
-1
 for an iron concentration of 0.087 M. As indicated by 
Fantechi et al.[196], doping of SPIONs with other metal atoms (like manganese) can improve the 
hyperthermia activity of magnetic nanoparticles. However, copper (5%, 10%, 15%,) doped iron oxide 
core (7 nm) resulted in very low SAR values, owing to the lower size of ferritin molecules coated 
magnetic core. 
The attractive therapeutic effects of SPIONs are demonstrated in various in vitro and in vivo 
scenarios. For example, 14 nm magnetic nanoclusters (with SAR value of 500 W g
-1
) killed almost 
74% of MCF-7 cancer cells in in vitro conditions, where a therapeutic temperature of 45 
0
C for 1 h was 
maintained [197]. The cell viability of HeLa cells was reduced to 42% as these cells were exposed to a 
temperature of 43°C (for 1000 s) which was induced by applying an alternating magnetic field to silica-
coated iron oxide nanoparticles [198]. In another study [199], the magnetic nanoparticles reveal their in 
vitro hyperthermia levels (42–45°C) in less than 200 s at a frequency of 26.48 kA m-1, in experiments 
with three different cancer cell lines (DA3, MCF-7 and HeLa). It was proven that the induction of 
apoptosis in cancer cells through magnetic nanoparticles increases with an increase in the 
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concentration/quantity and the size of these nanoparticles. Jadhav et al. [200] reported that the 
induction of apoptosis process in WEHI-164 tumour cells increased near to 80% when the quantity of 
sodium carbonate-stabilized-oleic acid-functionalized magnetic nanoparticles was increased from 0.22 
mg to 0.44 mg. Khandhar et al. [201] compared the survival rate of Jurkat cells for different Fe 
concentrations of magnetic nanoparticles. In a new study, polymer stabilized-iron oxide-graphene 
nanocomposite attained a heat of 42
°
C for a concentration of 2.5 mg/ml within 15 min of application of 
AMF at 418 Oe, where −40 ± 4% and −76 ± 3% of cell death was observed after 4 and 8 h incubation 
of nanocomposites with HeLa cells [202]. 
Hayashi et al. [192] reported that the exposure of magnetic nanoclusters to AMF intensity of 8 
kA m
-1
 and frequency of 230 kHz decreased the size of the tumor in female CB17/Icr-Prkdcscid mice, 
where the folic acid attached to magnetic nanoclusters (with an average SAR value of 248 W g
-1
) were 
injected intravenously. A significant temperature increase was observed in comparison to the 
surrounding tissues. Moreover, the volume of the tumour decreased to one-tenth times of the tumour in 
control mice after 35 days of treatment, where the life-span of hyperthermia treated mice extended by 
four weeks. In the study of Basel et al. [203] intraperitoneally injected magnetic nanoparticles helped 
in the reduction of tumour created via injection of Pan02 cells into C57BL/6 mice after getting exposed 
to 15–20 min of AMF, thereby improved the life expectancy rate of mice by 31%. In another case, the 
volume of SCCVII squamous cell carcinoma induced in mice was comparatively reduced through 
magnetic nanoparticles at an appropriate intravenous dose and applied a field of 38 kA m
-1
 at 980 kHz 
[204, 205]. In a similar fashion, polypyrrole coated Fe3O4 nanoparticles showed an SAR value of 487 
W/g, where the nanoparticles considerably inhibited the growth of myeloma tumour induced in Female 
CB17/Icr-Prkdcscid mice but completely when a combination of Fe3O4 nanoparticles and a 
chemotherapeutic drug at a quantity of 5 mg/kg was used for cancer therapy. 
In a recent study [206]  a novel injectable liquid to the solid phase transitional magnetic 
material, polymethylmethacrylate (PMMA)–Fe3O4, designed for highly efficient magnetic 
hyperthermia ablation of tumours was developed. The morphology characterization, magnetic 
properties and heating efficiency of PMMA–Fe3O4 were studied. The Fe3O4 particles were evenly 
distributed in the PMMA and the hysteresis curve of Fe3O4 and PMMA–Fe3O4 indicated that they were 
magnetic materials. When exposed to an alternating current magnetic field in vitro the magnetic 
PMMA–Fe3O4 generated heat. The increased temperature of excised bovine liver was positively 
correlated to the iron content and time, which suggested that the temperature inside the tumour was 
controllable. In the in vivo animal experiments a MB-231 breast cancer xenograft model was obtained 
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in nude mice. In this tumour model PMMA–Fe3O4 was injected precisely using guided ultrasound 
imaging which was proven by the computer tomography images. The tumours were completely ablated 
by a dose of 0.1 ml, 10% PMMA–Fe3O4 with 180 s exposure time in the magnetic field. The results 
demonstrated that PMMA–Fe3O4 was an excellent magnetic material for the localised magnetic 
hyperthermia ablation of tumours. 
The study presented by Grillo et al.[207] were based on the synthesis of sub-micrometer and 
magnetic polymer nanocomposite capsules (MPNCs) employing the oil-in-water emulsion/solvent 
evaporation method. The MPNCs showed a significant increase in the particle size from 400 - 800 nm 
as the magnetic loading in the organic–inorganic hybrids increases from 1.0% to 10%. The MPNCs 
presented high incorporation efficiency of Fe3O4@OA nanoparticles, excellent colloidal stability, and 
super-paramagnetic properties. Interestingly, electron microscopy results showed that the Fe3O4@OA 
nanoparticles were preferentially located at the surface of the capsules. Evaluation of the magnetic 
properties revealed that the saturation magnetisation and the blocking temperature of the MPNCs 
samples increased as a function of the Fe3O4@OA loading. All the MPNCs were heated when 
subjected to MH and demonstrate real specific absorption rates. When the MPNCs-cell interaction was 
tested lower cellular toxicity to healthy cells compared to cancer cells was indicated by MPNCs. These 
findings help in understanding the relationships between magnetic nanoparticles and polymeric 
capsules opening perspectives for their potential clinical uses as simultaneous heating sources and 
imaging probes in MH and MRI, respectively. 
In the work of Cristofolini et al. [208], the authors checked the applicability of magnetic 
nanocapsules (polyelectrolytes and magnetic Fe3O4 nanoparticles) to hyperthermia treatment. The 
hyperthermia effect was demonstrated by applying the RF magnetic field with maximum fields up to 
0.025 T and frequencies up to 430 kHz; they found sizable heating effects, with a heating rate up to 
0.46°C min
-1
. They also comment the effects of irradiation on capsules morphology that indicated their 
potential disruption use as nanocarriers of drugs that can be locally released on demand.  
MLs hybrid nanoparticles made of SPIONs coated with liposomes are emerging as the new class 
of bio-nanomaterials due to their potential applications in hyperthermia cancer therapy. The 
applicability of SPIONs for therapeutic purposes is increased when liposomes coat them. The 
hyperthermia treatment is based on the fact that SPIONs, when subjected to an oscillating magnetic 
field, generate heat and thus can kill tumour cells which are more sensitive to a temperature above 
41°C than the normal cells. Magnetoliposomes are very useful for hyperthermic applications. It is 
related to their properties as bilayer systems (high temperature dependence leading to corresponding 
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temperature response). The SPIONs of this kind are stable (surface-attached oleate molecule and 
dispersion in organic solvent ensure this stability). The transfer to aqueous media is also possible. This 
phase transfer relies on NP surface derivatization strategies replacing the originally grafted 
hydrophobic molecule with hydrophilic compounds or direct functionalization of the surface-grafted 
hydrophobic molecules themselves [209]. Surface chemistry not only determines the colloidal stability 
of the NPs but also their association to the liposome, i.e. whether they will be embedded in the 
hydrophobic bilayer or within the hydrophilic lumen [210]. 
Di Corato et al. [211] designed an approach to effective tumour therapy by creating a system 
based on dually loaded hybrid liposomes. The aqueous core includes loaded with iron oxide 
nanoparticles. The lipid bilayer, on the other hand, is equipped with a photosensitizer payload. This 
combination leads to the generation of singlet oxygen under laser excitation and heat production under 
alternating magnetic field stimulation. Thus, the photodynamic therapy is readily combined with 
magnetic hyperthermia. These liposomes address both therapeutic agents within tumour cells, and the 
combined PDT/MHT treatment resulted in total cancer cell death in vitro while total solid-tumor 
ablation was achieved in an in vivo rodent model. 
An excellent review dealing with recent advances in the application of SPIONs for in vitro and 
in vivo cancer theranostic was published by Kandasami and Maity [212]. 
 
5. Toxicity  
Iron oxide nanoparticles have proven to be convenient in a wide-ranging of applications besides 
its original design intention as high-performance seals in space application. Iron oxide nanoparticles 
have frequently been used for cells labelling and for in vitro separation and sorting and in vivo tracking 
magnetically. Although, the general assumption that IONPs are biocompatible, the data presented in the 
literature are sometimes conflicting. The most frequently suggested description of IONP toxicity 
encompasses the generation of reactive oxygen species (ROS), which causes lipid peroxidation, 
disrupting the phospholipid-bilayer membrane, resulting in cell death. IONPs are efficiently 
internalised by cells via endocytosis because of their nanoscale size. The IONPs are degraded by 
hydrolysis into iron ions within acidic organelles such as endosomes or lysosomes. The free iron ions 
are then transported through the organelle membranes through the divalent metal transporter-1 (DMT1) 
into the cytosol, where they undergo the Fenton reaction with the mitochondrial hydrogen peroxide 
(H2O2) to form hydroxyl radicals (•OH), a highly reactive ROS.  
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In the very recent work of Huang et al. [213], they posed hypotheses for toxicity of IONPs that 
are internalised into cells by endocytosis, depending on the pH of the environment to which the 
particles are exposed during their endocytotic transportation. IONP toxicity consideration is a 
necessary is we want to design and use IONP nanosystems with a vast range of clinical applications. 
The authors claimed a thermo-responsive liposomal system that contained ammonium bicarbonate 
(ABC, NH4HCO3) for localised drug delivery (Fig. 8). At an elevated temperature (42°C), the 
decomposition of ABC generates CO2 bubbles that create permeable defects in the lipid bilayer of the 
liposomes. The proposed model revealed that the local environment in cellular organelles, in which the 
pH-dependent degradation of IONPs and the release of iron ions occur, critically affects the amount of 
intracellular generated ROS, which causes lipid peroxidation and eventual cell mortality. In the 
literature concerning IONP toxicity [214-217] we observed contradictory results. Usually, toxicity 
could be severely related to the intracellular transport environment of the IONPs. For applications in 
cancer diagnosis and cell separation/sorting and tracking, the early endosomal escape of IONPs is 
crucial to preventing toxicity toward target cells. Conversely, the direct exposure of IONPs in 
lysosomes can significantly elevate their intracellular toxicity, possibly by improving their 
effectiveness in cancer treatment. 
 
Fig. 8. Schematic illustrations showing the structure of thermoresponsive bubble-generating liposomal 
system and its process of spatially precise, controlled intracellular liberation of IONPs in specific 
cellular organelles in various endocytotic stages. The degradation of IONPs, release of iron ions, and 
subsequent reactive oxygen species (ROS) generation within cells are indicated. IONPs: iron oxide 
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nanoparticles; ABC: ammonium bicarbonate; DMT1: divalent metal transporter-1.  Reproduced from 
[213] with permission from the American Chemical Society. Copyright 2017.  
 
The SPIONs materials are relevant in a vast number of biomedical applications; the question is 
that this type of applications requires knowledge about the potential interaction between nanoparticles 
and biosystems. Unfortunately, the results obtained concern still a restricted number of materials and 
products. It is a general opinion that individual assessment is needed when hazardous impacts by 
nanomaterials are considered, and the primary concerns are related to the size of the particles, their 
surface charge and their unspecific protein absorption ability.  
 
 
5.1. In vitro toxicity assessment 
In various studies [218, 219] it is shown that different in vitro toxicity tests used for 
determination of the toxicity of other that SPIONs nanoparticles could be applied to SPIONs as well, 
e.g. the viability of cells, i.e., cytotoxicity, oxidative stress, inflammatory reactions, and genotoxicity. 
In vitro nanotoxicity assays of SPIONS could be described shortly as follows [220]: 
 Nanoparticles cell interactions (including cell morphology and attachment of nanoparticles 
to cell membrane and further uptake) to be transformed into cellular response signals (cell 
decay or cytotoxicity, metabolic activity, antioxidant production due to oxidative stress, 
inflammation, genotoxicity); the respective assays are MTT Assay, PI Assay, BrdU Assay, 
LDH Assay (checking mitochondrial activity, DNA staining, DNA replication staining and 
membrane integrity assessment, respectively). 
 Nanoparticle cellular uptake was studied initially by Dextran-coated SPIONs as model 
systems [221-223]. It was found that different cells could be reliably labelled with SPIONs 
and further used for in vivo tracking procedures.  
Initial information about significant toxicity in SPIONs was presented by Mueller et al. [224] more 
than 20 years ago. This was followed by several studies of Berry et al. as well as by Gupta et al. [225-
228] showing that uncoated or dextran-coated SPIONs or bare SPIONs could cause varying degrees of 
cell death, vacuole formation and disruptions of the skeleton of dermal fibroblasts cytotoxicity and 
cytoskeletal damage. The coating of SPIONs by different proteins (lactoferrin, ceruloplasmin) has 
shown that the cell response could be modulated by the proper selection of surface. Later, van den Bos 
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et al. [229] demonstrated the toxic effect of Feridex material (dextran-coated SPIONs) in the case of 
macrophage exposure with decreased proliferation and cell death. Stroh et al. [230] have found that 
significant amount of SPIONs coated with citrate increase protein oxidation and oxidative stress.  
An interesting aspect of the in vitro toxicity of SPIONs is the comparison between their toxic 
impact and the toxicity (cancerogenic effect) of asbestos nanoparticles as done in [231-233]. It was 
convincingly shown by transmission electron microscopy and toxicity assays that murine macrophage 
cells exposed to bare SPIONs showed cytotoxicities nearing 90% of the asbestos-treated cultures. The 
authors explain the possible role of Haber – Weiss reactions due to the more rapid uptake and 
transportation of nanoparticles through the cells as compared of those of bare ions [231]. Significant 
morphological effects but relatively low toxicity upon a neuroblastoma cell line by SPIONs is reported 
in [234]. Au et al. have studied the impact of a commercial material (NanoSonics (Blacksburg, VA) 
based on SPIONs upon astrocytes and have found detectable effects on the mitochondrial function and 
decreased cell viability [235]. In a similarly designed study [236] Pisanic et al. present a model cell 
system which response to the toxicity impact of SPIONs coated with dimercaptosuccinic acid. It was 
found that the particles show a dose-dependent diminishing ability of the cells to survive and keep 
normal biological functions and morphology.  
It is proven that the surface coating of nanoparticles is of substantial importance for the 
stability, aggregate size and cellular interactions related to the SPIONs uptake in intercellular medium 
[237]. Diaz et al. [238] report on the uptake of SPIONs in relation to the cell type. The responses were 
entirely different indicating the role of the tested cell line. The same study shows that the number of 
particles per cell (not the concentration) might influence the response of the toxicological assay. It 
hinders the opportunity to find a direct relation between ROS production and cellular toxicity. For 
instance, in [239] is indicated that SPIONs coated with different saccharides could show variations 
drastically in cell responses and viability with minor changes in coatings.  
It is assumed that SPIONs could cause at least four primary sources of oxidative stress. 
According to several studies, it seems that there is a direct impact of SPIONs on ROS damage. 
Alekseenko et al. [240] examined the effects of uncoated SPIONs on neuronal cells. Theil et al. [241] 
investigated the role of ferritin (natural iron storage protein) which seems to have a pivotal role for the 
direct generation of ROS in rat synaptosomes. Further, Li et al. [242] stated that the redox active 
surface of SPIONs could seriously affect electron flow and alter mitochondrial functionality. Keeping 
this in mind it can be supposed that the use of active reductase enzymes for toxicological tests within 
the mitochondria of living cells leads to severe hazards.   
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Other recognisable targets for SPIONs toxicity seem to be the plasma membrane and proteins 
[243, 244] where nicotinamideadenine dinucleotide phosphate oxidase and its analogues are considered 
targets for SPIONs induced redox reactions. Take-up of SPIONs by phagocytic cells both in vitro and 
in vivo environments is extensively studied in [245-247].  
Inflammation induction has been investigated for both coated and uncoated SPIONs. Siglienti et 
al. [248] found that loading macrophages with SPIONs (uncoated) lead to increased interleukon-10 
production and inhibition of tumour necrosis factor α which could be an indication for 
immunomodulatory function. In the report of Hsiao et al. [249] about the response of SPIONs 
ferucarbotran loading on macrophages and come to the conclusion specific levels of nanoparticles 
cause secretion of tumour necrosis factor α and production of nitric oxide. It was also found [250] that 
significant inflammation response is observed when coated anionic SPIONs are used for labelling of 
human gingival fibroblasts (increase secretion of metalloproteases). Radu et al. [251] investigated the 
impacts of SPIONs on lipid peroxidation and antioxidative systems in lung fibroblast cells showing 
that an increased lipid peroxidation is observed. In the study of Choi et al. [252] in vitro cytotoxicity of 
iron oxide Fe3O4 and manganese oxide MnO was investigated by various toxicity assays where 
different factors were taken into account (the concentration of nanoparticles, incubation time, and 
different human cell lines). The toxicity has been checked by changes in pH and composition in cells 
and the tendency of SPIONs to adsorb proteins, vitamins, amino acids, and ions. As discussed by the 
authors some of the results obtained show that the toxicity assays used for assessing SPIONs are not 
entirely adapted for this goal and could lead to wrong interpretation. 
 
5.2. In vivo toxicity assessment 
Natarajan et al. [253] employed magnetic nanoparticles with diameters of 20, 30, and 100 nm 
and evaluated their application for alternating magnetic field therapy and their in vivo performance 
depending on their size. The results showed that tumour targeting and heating capacity depended on the 
size of the nanoparticles.  
SPIONs are often determined as biocompatible when no significant toxic effects in vivo are 
shown. Jain et al. [254] report that in vivo administration of SPIONs did not lead to an adverse effect 
on liver function. It is worth to mention that the correct prediction of the biological fate of SPIONs is 
strongly dependent on the composition and amounts of associated proteins at the surface of the 
nanomaterial. For instance, oleic acid/pluronic-coated SPIONs (i.e., 55% of the intravenously injected 
dose) were found to accumulate in the liver of rats; however, elimination of dextran-coated SPIONs, 
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via urine and feces, was around 25% of injected dosage in the same animal model [255]. The 
differences in these studies are probably related to the protein corona composition of the nanoparticles.  
The physicochemical parameters of the nanoparticles are usually accepted as an important 
factor for cell uptake. Mahmoudi et al. [256] indicate that cell type is also an important feature for 
cellular uptake, intracellular fate, and toxic response of the nanoparticles. As shown in this study 
SPIONs having a different surface chemical composition (uncoated and cyanoethyltrimethoxysilane - 
and aminopropyltriethoxysilane-coated) revealed toxic impacts on human brain cells at iron 
concentrations above 2.25 mM, whereas the same concentration of NPs was acceptable for human 
kidney cells.  
Hanini et al. [257] tested SPIONs in vivo and could confirm that SPIONs induced toxicity in the 
liver, kidneys, and lungs; however, the brain and heart organs remained unaffected. It is in good 
agreement with earlier statements that negatively charged SPIONs do not cause serious changes in the 
actin skeleton of heart cells but could disrupt the actin skeleton in kidney and brain. In the study of 
Chertok et al. [258] on the possibility of applying SPIONs as drug delivery remedy in the magnetic 
targeting of brain tumours is shown that accumulation of SPIONs in gliosarcomas in rats could be 
enhanced by suitable concentration of nanoparticles and optimal parameters of the magnetic field 
without any toxicity effects.  
 
6. Computational Study of SPIONs 
From an experimental point of view, the molecular design of SPIONs for biomedical 
applications is a great challenge. At the nanolevel, the efficiency of molecular design of SPIONs 
depends on the fundamental understanding of structural concepts and interfacial interactions in the 
nanoparticle-coating complex. For example, it is essential to know what nanoparticle composition (iron 
oxide phase and an organic/inorganic coating) is suitable for a given biomedical application and why? 
Moreover, under an applied magnetic field, superparamagnetic particles can self-assembly in 
structures, such as chains and bundles. For stimuli-responsive materials and magnetophoresis 
applications, such self-assembly is the desired effect. On the other hand, for some biomedical 
applications, the self-assembly should be avoided because it by reducing the biocompatibility, by 
causing ageing or time dependency in properties [259]. Therefore, at the microscopic level, the 
efficiency of SPIONs design is determined by the state-of-the-art in methods for self-assembly, i.e. by 
the knowledge how to control the nanoparticle-nanoparticle and nanoparticle-environment interactions. 
However, the molecular design of SPIONs is still largely empirical, and the system complexity limits 
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their experimental multi-scale characterization in bio environment. This hampers the possibility to 
guide the synthesis and to tune the performance of SPIONs materials for biomedical applications. 
Therefore, computer simulations and modelling methods play a crucial role in the improvement of 
molecular designs strategies in SPIONs with biomedical applications.  
In this section, we will give a brief overview of the application of the computational methods 
for SPIONs with attractive biomedical properties. The overview is focused mainly on three widely used 
and very popular types of computer simulations for SPIONs - molecular dynamics (MD), Monte Carlo 
(MC) and density functional theory (DFT). The time evolution of a system composed of interacting 
particles - atoms, molecules or their clusters can be theoretically predicted by using MD method [260, 
261]. In this simulation technique, the potential energy of the particle-particle interactions is described 
by using interatomic potentials or molecular mechanics force fields, the trajectories of the particles are 
obtained by numerical solution of Newton's equations of motion, and means of statistical mechanics 
derives the macroscopic properties of the system. Monte Carlo method relies on equilibrium statistical 
mechanics [262]. It uses random numbers to generate an ensemble of representative configurations of 
the system, from which thermodynamic properties can be calculated. Monte Carlo simulations are free 
of solving Newton's equations of motion and do not provide information about the time evolution. 
Similar to the case of MD, in MC the potential energy of the particle-particle interactions is described 
by using interatomic potentials or molecular mechanics force fields. Density functional theory is a 
quantum-mechanical method and is based on the solution of the Schrödinger equation. Therefore, DFT 
approach is applied to investigate the electronic structure and properties of atoms, molecules and solids 
– information that is crucial for the SPIONs performance but cannot be obtained by MD and MC 
simulations. By using DFT method one can model and predict molecular structures, IR and UV-vis 
spectra, ionisation potential and electron affinity, as well as conducting optical and magnetic properties.  
MD simulations have been used in the context of SPIONs to study interfacial interactions of 
coated nanoparticles, adsorption properties of molecules, proteins and gold nanoparticles. Also, the 
effect of the magnetic field to permeabilization to cell membranes is also explored by MD calculations. 
Qiang et al. [263] applied atomistic molecular dynamics simulations and COMPASS force field 
(Condensed-phase Optimized Molecular Potentials for Atomistic Simulation Studies) to investigate the 
interfacial interactions in a Fe3O4 surface coated with chitosan. They calculated the interaction energy, 
radial distribution function and concentration profiles for chitosan adsorbed on different Fe3O4 
crystallographic planes. The result indicated that the interaction of chitosan with Fe3O4 (1 1 1) surface 
is stronger than that with (1 1 0) and (0 0 1) surfaces. The higher probability explains this of formation 
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of hydrogen bonds between the amino groups of chitosan and the oxygen atoms from the (1 1 1) 
surface. In another theoretical study by Qiang et al. [264] the same computational strategy was used to 
reveal the interfacial interaction between Fe3O4 (1 1 1) crystallographic plane and different 
biocompatible polymers. In particular, the authors explored coatings based on polysaccharides 
(chitosan and dextran) and polyesters (polyethylene glycol, polyethylenemine, polylactic acid, and 
poly(lactic-co-glycolic) acid). The MD study reveals stronger interfacial interactions in the case of 
polysaccharides than in the case of polyesters. The stronger interfacial interactions with 
polysaccharides are suggested to originate from the presence of hydrogen donor groups (such as 
hydroxyl and amino groups) that ensure hydrogen bond formation with the oxygen atoms from the 
Fe3O4 (1 1 1) surface.   
Using molecular dynamics simulations and charge consistent-valence force field Harris et al. 
[265] investigated the adsorption of sebacic acid and 1,10-decanediol on the surfaces of Fe3O4  
nanoparticle (d ≤ 2.6 nm). The calculations predicted stronger interfacial interactions in the case of 
1,10-decanediol coating and showed that only this surfactant inhibits the oxidation of the Fe3O4 
nanoparticle for the given size range. The theoretical findings are additionally confirmed by 
experimentally obtained transmission electron micrographs and X-ray diffraction spectra. Two years 
later, Harris et al. [266] reported theoretical results on the adsorption of oleic acid and oleylamine acid 
on Fe3O4 spherical nanoparticles (d=2.6 nm) obtained by the same computational procedure. The 
organic coatings by different oleic acid/oleylamine acid ratios, are modelled, as well as by changing the 
degree of protonation of the oleic acid. The authors concluded that the combination of two surfactants 
is crucial for the synthesis of Fe3O4 nanoparticles because the proton accepting properties of the 
oleylamine acid regulate the electrostatic pressure, which prevents for oleic acid desorption caused by 
an excess of free protons. Such regulation of the electrostatic pressure and stabilisation is possible only 
at an ideal ratio of oleic acid/oleylamine acid ratios, which ensures a perfect fit between the surface 
charge of the nanoparticle, free proton concentration in the dispersion medium, and zeta potential. The 
computational results are corroborated by transmission electron microscopy (TEM), FTIR, and pH 
measurements. 
Yue et al. [267] applied the molecular dynamics method and COMPASS force field. The 
authors investigated the deposition of gold nanoparticles on the Fe3O4 nanoparticles coated with an 
intermediate layer. The SPIONs core is modelled by Fe3O4 (1 1 1) surface, and the intermediate layer is 
composed by oleylamine, oleic acid, polyethylimine, polymethylacrylic acid, 3-aminopropyl 
triethylsilane, or tetraethylorthosilicate. Their results indicated that the intermediate layer introduces 
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new functional groups such as carboxylates, amines, or thiols, which ensure better adsorption of gold 
nanoparticles on the Fe3O4 (1 1 1) surface. Moreover, they showed that the strength of linkage between 
the Fe3O4 (1 1 1) surface and the gold nanoparticles depends on the type of the functional groups 
present in the intermediate layer. The intermediate coatings with amino groups (oleylamine, 
polyethylimine and 3-aminopropyl triethylsilane) form a strongly bonded “primary layer” on the Fe3O4 
(1 1 1) surface but loosely packed “secondary layer”, which is critical for the subsequent golden 
nanoparticles deposition. The authors also considered the interaction of cysteine with 
Au/polyethylimine/Fe3O4 nanocomposites and showed that the amino acid relatively strong absorption, 
which can be useful for functional exploration in biomedical applications, Fig. 9. 
 
Fig. 9. Molecular structure of (A) cysteine, (B) methinone, and (C) arginine and (D) snapshots 
of the Au/PEI/Fe3O4 nanocomposite with the addition of cysteine at simulation time of 0 and 200 ps - 
Reprinted with permission from Yue J, Jiang X, Yu A, J. Phys. Chem. B, 2011, 115: 11693 [267]. 
Copyright [Copyright © 2011 American Chemical Society]. 
 
Yu et al. [268] employed molecular dynamics simulations to reveal the adsorption of proteins, 
in particular, bovine serum albumin, on SPIONs. The bovine serum albumin proteins were modelled 
with an atomistic resolution by using the CHARMM27 force field, and the NPswere simulated as 
clusters of Lennard-Jones spheres. The solvent effects were also included by employing a generalised 
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Born implicit solvent model. The authors computed the maximum theoretical number of albumin 
molecules adsorbed onto the NPs (d=6 nm) by simulating SPIONs complexes with 1, 2, 4, 8, 10, and 
12 protein molecules. The computational results suggest monolayer of 10 bovine serum albumin 
molecules on one NP, which is also confirmed by experimental TEM and UV-vis measurements. The 
MD simulations also revealed three different stages in the adsorption process of bovine serum albumin 
proteins: (1) the protein migrates from the bulk solution in order to get in touch with the NP surface, (2) 
the protein spreads out on the NP surface in a view to increase the contact region with the core (3) the 
protein relaxes to a more compact configuration The findings suggested that due to its protein-resistant 
surface the bovine serum albumin-SPIONs complex can be used as an efficient carrier for targeted drug 
delivery in vivo.  
Recently, Pedram et al. [269] explored the magnetic field effect to deliver SPIONs through the 
blood-brain barrier using molecular dynamics simulations and CHARMM27 force field. The solvent 
effects were also taken into account by using the TIP3P method for water. The endothelial cell 
membrane of the blood-brain barrier is modelled as a lipid bilayer of palmitoyl oleyl phosphatidyl 
choline (POPC). The SPIONs are simulated as are spherical shaped particles with 2 nm size with a gold 
coating (2 Å). The calculations reveal that by applying a magnetic force in the range of pN, the SPIONs 
open a gap in the membrane and cross it, Fig. 10. Moreover, this process is reversible and totally non-
invasive. Afterwards, the SPIONs can move through the cells with a much lower magnetic force. The 
results show that the maximum magnetic force depends on the nanoparticle size and that the crossing 
time can be controlled by variation of the magnetic pattern and magnetic field strength. 
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Fig. 10. Several Steps of Crossing through the blood-brain barrier (BBB) These steps come from 
simulation, and the main goal is to show how the membrane is opened and how it can rehabilitate itself 
upon the completion of the crossing. Reprinted with permission from Pedram M Z, Shamloo A, Alasty 
A, Ghafar-Zadeh E, Biosensors 2016, 6: 25 [269]. 
The Monte Carlo method is a stochastic method and has been employed to generate a statistical 
or probabilistic model for understanding particular systems. The MC calculations were performed to 
confirm the experimentally observed behaviour of Fe3O4 nanoparticles and SPIONs. MC calculations 
were conducted to compute: adsorption of molecules as water and surfactant molecules, the stability of 
dispersions, and to simulate the T2 relaxation in magnetic resonance experiments.  
Tombácz et al. [270] investigated the adsorption of water vapour on the surface of Fe3O4 
nanoparticles by using grand canonical Monte Carlo method. The authors applied Universal force field 
(UFF) and TIP4P model of the water. The NP surface is simulated as a (001) and (011) surface of the 
magnetite crystal. The theoretically predicted adsorption isotherm reproduces very well the measured 
ones. The calculations show the adsorbed water is organised in a layered structure, which occurs by 
simultaneous formation of several molecular layers. The simulations also suggest that the adsorption 
mechanism is similar to nucleation, i.e. new water molecules are attracted to the surface regions that 
already accommodate a large amount of water. 
Experimental results of Kumar et al. [271] show a different state of dispersion for Fe3O4 
nanoparticles in an aqueous medium as a function of the nanoparticle coating. Namely, aggregates 
formation for Fe3O4 nanoparticles coated with citric acid and an individual isolated state for Fe3O4 
nanoparticles coated. MC calculations were performed to confirm the experimentally observed 
behaviour of the aqueous dispersions. To get further insight on the stability of the dispersions, the 
authors simulated the effect of four variables: particle volume percentage, particle diameter, shell 
thickness, and grafting density. Based on the theoretical predictions, the authors were able to 
recommend a possible range of values for these four variables, which can be directly applied 
experimentally to obtain a stable aqueous dispersion of isolated particles. 
Matsumoto et al. [272] used MC method to simulate the T2 relaxation induced by clusters of 
SPIONs in magnetic resonance experiments. The authors calculated the T2 relaxation as a function of 
different geometric characteristics of the nanoparticle clusters: particle size, the number of particles per 
cluster, interparticle distance, compact or linear cluster shapes. The simulations reveal that for small 
particles, the cluster shape and cluster density significantly affect the T2 relaxation, while the for large 
particles the T2 relaxation become dependent on the cluster geometry only when the interparticle 
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distances exceeded ten times the particle diameter. These results suggest that the performance of the 
aggregation-based sensors can be controlled by optimising the SPIONs size and coating thickness and 
that the changes in the magnetic resonance imaging contrast could be obtained by tuning the geometric 
parameters of the individual clusters. 
Martinez-Boubeta et al. [273] performed MC simulations on SPIONs to describe their magnetic 
hyperthermia performance theoretically. The MC calculations were carried out by using atomistic and 
macrospin approximation approaches. The atomistic MC calculations corroborate experimental 
measurements and show larger anisotropy in the case of the cubic than regarding spherical 
nanoparticles. Also, the authors reported a qualitative relationship between the heat power and the 
interparticle interactions. Namely, they demonstrated that the assembling of the cubic nanoparticles in 
elongated chains represents a promising way to increase the hyperthermia performance. 
In their theoretical work, Russier et al. [274] reported MC simulations on the mean size and 
polydispersity effects in densely packed iron oxide magnetic nanoparticles assemblies. The 
nanoparticles are modelled as uniformly magnetised spheres coated with the insulating organic layer. 
The results demonstrate that the linear magnetic susceptibility as a function of the median diameter 
may present a plateau. This was shown to lead to a quasi- independence of the magnetisation on the 
median diameter at low external fields and high concentration. The magnetocrystalline anisotropy is 
then proved to play a role for larger values of the field when the particles remain in the 
superparamagnetic regime in agreement. 
Using three-dimensional MC simulations and electron magnetic resonance measurements, 
Castro et al. [275] explored a fluid composed of Fe3O4 nanoparticles coated with dodecanoic acid 
molecules and dispersed in hydrocarbons. The results reveal that the grafting (surface density of 
surfactant molecules) of isolated particles increases with the particle concentration, while the grafting 
of bonded nanoparticles shows a more complicated behaviour. The simulations demonstrate that the 
adsorbed molecules have a tendency to dissociate when the surfactant layers of two nanoparticles get in 
contact. On the other hand, the repulsion between the apolar solvent and the polar heads dissociated 
molecules increases the possibility for re-adsorption of the surfactants on available adsorption sites. 
The results suggest that the ratio between the grafting (steric repulsion) and Hamaker constant (van der 
Waals attraction) determines the degree of nanoparticle agglomeration. 
Many DFT studies have emphasised on the structural, electronic, catalytic, and magnetic 
properties of Fe2O3 and SPIONs. Methods developed in the framework of DFT are currently the most 
popular and effective approaches used in solid state physics, quantum chemistry and nanotechnology.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
45 
 
DFT investigation of the stability of SPIONs coatings in the physiological environment was 
reported by Aschauer et al. [276]. The DFT calculations were performed in vacuo with the PBE 
functional, taking into account van der Waals correction. The SPIONs were modelled by the (1 1 0) 
surface of Fe3O4 and coating molecules were represented by water, polyvinyl alcohol, polyethylene 
glycol, monomer and dimer of glycine as a prototype short peptide. The theoretical results show that 
the adsorption energy decreases in the following order: polyvinyl alcohol > water > polyethylene 
glycol ~ glycine. This proposes the stability of the polyvinyl alcohol coatings in the presence of water 
and polypeptides. The higher adsorption strength of polyvinyl alcohol was explained by the presence of 
OH side-group, which binds significantly stronger to the surface than the oxygen from the polyethylene 
glycol or the amino group of the peptide bond. 
Guénin et al. [277] reported a combined DFT and experimental study on the ligand exchange on 
the surface of SPIONs dispersed in water. The authors compared two strong chelating agents, 
containing catechol and bisphosphonate moieties. The DFT calculations were performed with the 
exchange-correlation functional of Staroverov, Scuseria, Tao and Perdew functional (TPSSh), and they 
served to elucidate the interactions between catechol/bisphosphonate groups and the nanoparticle 
surface. The calculated spectra show good agreement with the FTIR measurements and confirm that 
the adsorption of ligands is realised through their chelating groups. The experimental results 
demonstrate that catechol and bisphosphonate molecules can be exchanged and that the ligand 
exchange increases by using a large excess of bisphosphonate and sonication. 
Fouineau et al. [278] demonstrated that the DFT simulations with the Perdew, Burke, and 
Ernzerhof (PBE) functional could be used to elucidate the electronic transfer and the binding mode 
between coating ligands of biological interest and the SPIONs surface. In particular, the authors 
investigated γ-Fe2O3 nanoparticles functionalized with dopamine; the results reveal that dopamine 
binds preferentially to octahedral sites and that the linking bond is with covalent nature. Experimental 
data corroborate the results, and the agreement proves that the DFT simulations can serve as an 
appropriate supplemental approach to interpreting 
57Fe M ssbauer spectra of SP O s. 
By using DFT method, de Leeuw et al. [279] investigated the hydration behaviour of three iron 
(hydro)oxide minerals, including hematite. The results suggest that the interaction with water 
molecules is done mainly between the oxygen and the surface iron ions from the hematite surface, 
followed by hydrogen-bonding to surface oxygen ions. The calculations show relatively larger 
hydration energies for hematite and dissociative adsorption of water molecules. 
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Faraudo and co-workers [280] explored and analysed magnetophoretic separation of 
superparamagnetic particles under well-controlled magnetophoretic conditions. The authors obtained a 
simple analytical solution for the process of noncooperative magnetophoresis by which its kinetics can 
be predicted based on particle characterization data, such as size and magnetisation. In another paper 
by Faraudo et al. [281] devoted to the theoretical aspects of cooperative magnetophoresis of 
superparamagnetic colloids, the authors analysed the physicochemical conditions at which reversible 
aggregation occurs, the timescale of aggregate formation and their aggregates shape. In the case of 
colloids stabilised electrostatically, they found that the interaction potential between two 
superparamagnetic particles is such that allows the reversible formation of aggregates. Also, the 
authors reported that the particle aggregation is a fast process and the preferred aggregation is lateral 
over the tip-to-tip aggregation for long chains. These findings are in agreement with experimental 
observations. An excellent review on computational methods for qualitative prediction of self-assembly 
processes of SPIONs can find in the very recent publication of Faraudo et al. [259]. 
The above-presented investigations clearly illustrate the predictive power of the theoretical 
modelling for efficient design of SPIONs structures, aggregation behaviour and properties. To go 
deeper in the understanding of the intimate structural, chemical, and physical properties of 
functionalized SPIONs, we want to focus the attention of the reader to the role and impact of the 
computational methods rely on multiscaling approach.  
 
Conclusions: 
The assessment of the role of SPIONs as a versatile platform for medical development requires 
more in-depth insight knowledge and constant study of relationships between nanoparticles size and 
size distribution, shape, surface coating, magnetic properties and their biological application. The focus 
of the review is on recent progress in this field, and the diverse utilities of SPIONs for diagnostics, 
therapeutics and theranostics are outlined. A general discussion on the in vitro and in vivo toxicities of 
SPIONs has been provided while there are still some issues that need to be explicitly addressed during 
the engineering of SPIONs for clinical use. It is crucial to understand the potential risks associated with 
exposure to SPIONs and the physiological effects produced by the surface coatings utilised for 
functionality considering the broad applications of SPIONs. The review also has highlighted the ability 
of computational models as a valuable tool for better understanding of the system to obtain proper 
materials with the desired behaviour and properties. In this respect, theoretical methods, in the form of 
analytical equations or computational methods could be very helpful to shed light on the topic.Through 
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the persistent efforts by multidisciplinary and multilevel approaches, there is a great potential for further 
breakthrough developments in SPIONs designs for nanomedicine application. 
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